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1) Introduction 
 
1.1) Purinergic Receptors  
 
Purinergic receptors were firstly classified by Gordon in 1986 on the basis 
of  their pharmacological profile. In 1997 the International Union of Basic 
and Clinical Pharmacology (IUPHAR) amended the classification by 
including the molecular structure. Accordingly, purinergic receptors are 
currently classified  in two groups: P1 and P2 receptors.  
Physiological agonist of P1 receptors is adenosine, while physiological 
agonist of P2 receptors agonist are ATP (adenosine-5'-triphosphate) and 
other nucleotides. This thesis focuses on P2 receptors.  
 
1.1.1) P2 receptors 
 
P2 receptors are divided into two subgroups: P2Y and P2X (Apasov et al. 
1995; Ralevic and Burnstock, 1998).  
 
1.1.2) P2Y receptors 
 
P2Y receptors  also referred to as “metabotropic”, G protein-coupled 
receptors, of about  41 KDa MW, with a cytoplasmic C-terminal and an 
extracellular N-terminal domain (fig.1).  
Nucleotide binding triggers a conformational change, that switches on the  
G protein which in turns stimulates a phospholipase C, that drives the 
inositole 3-Phospate (InsP3 ) and diacylglycerole (DAG) accumulation in 
the cytoplasm. InsP3 releases Ca2+ from the intracellular stores and 
triggers activation of cellular Ca2+ -dependent responses.  Eight P2Y 
receptor subtypes have been cloned and characterized: P2Y1, P2Y2, P2Y4, 
P2Y6, P2Y11, P2Y12, P2Y13, P2Y14.  
In general all  P2Y receptors are activated by ATP, although UTP (uridine 
5'-triphosphate) is a better agonist at P2Y4 and P2Y6 receptors, while ADP 
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(adenosine 5′-diphosphate) is a better agonist at  P2Y1, P2Y12 and  P2Y13  
and UDP-glucose (uridine 5'-diphosphate-glucose) activates  P2Y14.  
All P2 receptors trigger phospholipase C activation through protein G. In 
particular P2Y1, P2Y2 induce phospholipase Cβ activation and inhibit 
adenylate cyclase (AC) through Gq/11 and Gi respectively (Table 1). 
 
 
 
 
 
 
 
 
 
Fig. 1. P2Y receptors structure 
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Receptor  Main Distrtibution Agonists Antagonists  Signal induced 
P2Y1 
Brain epithelial and 
endothelial cells, platelets, 
immune cells, osteoclests 
ATP, MRS 2365, 2-
MeSADP, ADP, ADPβS 
MRS 2500, MRS 2279, 
MRS 2179 PLCβ/IP 3 Ca 
2+ 
P2Y2 
Immune cells, epithelial 
and endothelial cells, 
kidney tubules, osteoblasts 
ATP, UTP, MRS 2698, 
INS 365, INS 37217, 
UTPγS, Ap4A, MRS 2768 
RB2, AR-C 126313, 
Suramin  PLCβ/IP 3 Ca 
2+ 
P2Y4 Endothelial cells and placenta 
2'-azido-dUTP, UTPγS, 
UTP, ATP, Ap4A, CTP, 
ITP 
ATP (human), RB2, 
Suramin PLCβ/IP 3 Ca 
2+ 
P2Y6 
Airway and intestinal 
epithelial cells, spleen, 
placenta, T-cells, thymus 
MRS 2693, UDPβS, PBS 
0474, INS 48823, Up3U, 
UDP, UTP, ATP 
MRS 2578, RB2, PPADS 
PLCβ/IP 3 Ca 2+; 
adenylate 
cyclase 
P2Y11 Spleen, intestin, granulocytes 
ATPγS, ARC 67085MX, 
BzATP, ATP   NF 157, Suramin, RB2 
Adenylate 
cyclase 
P2Y12 Platelets, brain (glial cells), microglial cells 2-MeSADP, ADP 
ARC 69931MX, AZD 
6140, INS 50585, RB2, 
2-MeSAMP 
Adenylate 
cyclase 
P2Y13 Spleen, brain, limph nodes, bone marrow 
ADP, 2-MeSADP, 2-
MeSATP, ATP   
ARC 69931MX, ARC 
67085, MRS 2211 
protein G 
coupled 
P2Y14 
Placenta, mast cells, 
adipose tissue, stomach, 
intestine, discrete brain 
regions 
MRS 2690, UDP, UDP-
glucose, UDP-galactose None ? 
2-MeSATP: 2-metiltioadenosin -5'-triphosphste; α,β-MeATP: α,β-metilenadenosin-5'-triphosphate; TNP-GTP: 
2'(3')-O-(2,4,6-trinitrophenil)guanosin-5'-triphosphate; BBG: Brilliant Blue G 
 
Table 1. Agonists, antagonists, tissues of distribution and  
signal transducted by P2Y receptors  
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1.1.3) P2X receptors 
 
P2X are ligand-gated ionotropic receptors (Ligand-gated ion channel, 
LGICs) (Khakh et al., 2001). Receptor activation leads to cationic (NA+, 
K+, Ca2+, Mg2+) fluxes through the plasma  membrane. In general, P2X 
receptors are characterized by about 400 aa long, with two 
transmembrane hydrophobic units and a large extracellular region, with 
10 cystein and 2-6 sites of glycosilation. Both the N-terminal and C-
terminal ends are cytoplasmic (fig.2) (North et al., 1997). 
P2X receptor family includes seven subtype named P2X1, P2X2, P2X3, 
P2X4, P2X5, P2X6 and P2X7. They were originally characterized in 
excitable tissue, but it is now clear that they are virtually ubiquitous 
(Table 2). 
 
 
 
 
 
Fig. 2. P2X receptors structure 
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Receptor  Main Distrtibution Agonists Antagonists  Signal induced 
P2X1 
Smooth muscle, platelets, 
cerebellum, dorsal horn 
spinal neurons 
ATP, BzATP, 2-MeSATP, 
α,β-MeATP (rapid 
desensitization) 
NF 449, TNP-ATP, NF 
279, TNP-GTP, IP5I I Na/K/Ca
2+ 
P2X2 
Smooth muscle, brain, 
pancreas, retina, 
chromaffin cells, autonomic 
and sensory ganglia 
ATP, BzATP, 2-MeSATP, 
α,β-MeATP  RB2, PPADS, Suramin  I Na/K 
P2X3 
nociceptive sensory 
neurons, NTS, some 
sympathetic neurons 
ATP,  2-MeSATP, α,β-
MeATP (rapid 
desensitization), Ap4A 
 TNP-ATP, PPADS, 
A317491, NF110, TNP-
GTP, IP5I 
I Na/K/Ca2+ 
P2X4 microglia, testis, colon, endothelial cells 
ATP,  α,β-MeATP, CTP, 
Invermectin 
(potentiates) 
5-BDBD, TNP-ATP, 
PPADS, BBG I Na/K 
P2X5 
proliferating cells in skin, 
gut, bladder, thymus, 
spinal cord, heart, adrenal 
medulla 
ATPγS, ATP, α,β-MeATP   PPADS, BBG, Suramin I Na/K/Ca2+ 
P2X6 Brain, motor neurons in spinal cord 
no functional 
homomultimer None I Na/K/Ca
2+ 
P2X7 
macrophages, mast cells, 
microglia, pancreas, skin, 
endocrin organs 
ATP, BzATP, 2-MeSATP, 
α,β-MeATP  KN 62, BBG 
I Na/K/Ca2+;  pore 
formation 
2-MeSATP: 2-metiltioadenosin -5'-triphosphste; α,β-MeATP: α,β-metilenadenosin-5'-triphosphate; TNP-GTP: 
2'(3')-O-(2,4,6-trinitrophenil)guanosin-5'-triphosphate; BBG: Brilliant Blue G 
 
Table 2. Agonists, antagonists, tissues distribution and  
signal transducted by P2X receptors 
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1.2) P2X7 receptor 
 
P2X7 receptor is one of the most interesting members of the P2X family. 
It was originally cloned from a rat cervical ganglion cDNA library 
(Surprenant et al., 1996), but further evidences revealed P2X7 expression 
in many other tissues such as macrophages, monocytes, microglial cells 
and spleen (Table 2).  
Unlike the other P2X receptors, P2X7 receptor has an unusually long 
cytoplasmic C-terminal end (fig. 3A), that endows P2X7 with the ability to 
generate a non selective membrane pore that allows transmembrane 
fluxes to cations, nucleotides and other small hydrophilic molecules of MW 
up to 900 Da (fig 3B). Truncation of the cytoplasmic tail prevents the 
channel-to-pore transition (Surprenant et al., 1996). Channel-to-pore 
transition is hastened by prolonged stimulation with ATP or by stimulation 
with high (hundred micromolar) ATP concentrations. ATP removal or 
hydrolysis causes the pore to close. Since P2X7 does not inactivate, i.e. 
remains open so far it is boun to its ligand, high ATP concentration may 
cause cell death by causing sustained pore opening (Di Virgilio et al., 
1998). Experimental evidence suggests that maximal activation induces a 
P2X7 channel diameter expansion from a 0,8 to 2-5 nm in HEK293-
transfected cells (Virginio et al., 1999), as well as in mast cells (Cockcroft 
and Gonperts, 1979), mouse peritoneal macrophages (Steinberg et al., 
1987), human macrophages (Falzoni et al., 1995), dendritic cells (Mutini 
et al., 1999), J774 and BAC1.2F5 macrophage cell lines (Steinberg et al., 
1987; El-Moatassim and Dubyak, 1992), mouse microglial cells (Ferrari et 
al., 1996). Pore size is smaller in human fibroblasts (Solini et al., 1999), 
mouse spleen and thymus cells (Di Virgilio et al. 1989) and human 
lymphocytes (Wiley et al., 1993).  
Accordingly, B lymphocytes from CLL (Chronic Lymphoid Leukemia) 
patients show ATP-stimulated Na+, K+, Ca2+ and ethidium (394 Da) fluxes, 
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but are impermeable to propidium (414 Da) flux, as well as other to larger 
molecules (Wiley et al., 1993). 
P2X7 expression is modulated during cell growth and differentiation as 
well as by the treatment with cytokines. In fact P2X7 is expressed by only 
15% of monocytes isolated from peripheral blood, and by 40-60% of 
those differentiated in vitro (Hickman et al., 1994; Blanchard et al., 
1991). Interferon-γ (INF- γ) and Concanavalin A (ConA), but not 
lipopolysaccharide (LPS) enhance P2X7 expression, does not (Blanchard et 
al., 1991; Falzoni et al., 1995). Increased P2X7 expression enhances ATP 
sensitivity (Falzoni et al., 1995).  
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Fig. 3. (A) P2X7 receptor structure. (B) P2X7 channel-to-pore conversion. (C) P2X7-
mediated cell responses. 
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1.2.1) P2X7 receptor pharmacology. 
 
The favorite P2X7 receptor ligand is ATP, but its activity can be modulated 
by other pharmacological ATP analogues.  
2’,3’-(4-benzoil)-benzoil-ATP (BzATP) is the most common P2X7 receptor 
agonist, but it is not absolutely selective for P2X7 as it can act on P2X1 
and P2X3 receptors (Evans et al., 1995).  
Various antibiotics can modulate directly or indirectly P2X7 receptor 
activity: geldanamycin (GA) has been showed to potentiate P2X7-
dependent response, by binding the amino-terminal ATP-binding pocket of 
“Heat-Shock” protein 90 (HSP90), thus preventing its interaction with 
P2X7 itself (Adinolfi et al., 2003). Polimixin B (PMB), known for its ability 
to neutralize bacterial endotossin (LPS), potentiates P2X7 stimulation by 
ATP, thus lowering the cytotoxic threshold of otherwise ineffectual ATP 
doses (Ferrari et al., 2004).    
Oxidized ATP (oATP) is largely used as a P2X7 antagonist, even though 
this covalent reagent is likely to have low selectively has its highly 
reactive aldehide group can generate a Shiff base with any unprotonated 
lysine close to any ATP-binding site on the plasma membrane (Murgia et 
al., 1993; Beigi et al., 2003; Di Virgilio et al., 2004).  
One of the first, potent and selective P2X7 inhibitors was KN-62 (Garget 
and Wiley, 1997). More recently, a family of highly selective and potent 
KN-62 pharmacologic analogs with a strong interleukin-1β (IL-1β)-
blocking activity have been synthesized (Baraldi et al., 2003).  
Other inhibitors have been synthesized by Pharma industry: 
1. A 438079 hydrochloride is a competitive P2X7 receptor antagonist. 
The compound is devoid of activity at other P2 receptors and 
possesses antinociceptive activity in models of neuropathic pain in 
vivo (Donnelly-Robersts and Jarvis, 2007; McGaraughty et al., 
2007).  
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2. A 740003 is a potent, selective and competitive P2X7 receptor 
antagonist (EC50 values are 18 and 40 nM for rat and human 
respectively). This compound displays selectively over a variety of 
P2X and P2Y receptors up to concentration of 100 µM. 
Nevertheless, it reduces nociception in animal models of persistent 
neuropathic and inflammatory pain (Honore et al., 2006; Donnelly-
Roberts et al., 2009).  
3. AZ 10606120 dihydrochloride is another potent P2X7 receptor 
antagonist. Differently from those described in advance, AZ 
10606120 binds in appositive cooperative manner to sites distinct 
from, but coupled to, the ATP binding site and act as a negative 
allosteric modulator (Michel et al., 2007; Michel et al., 2008a).  
4. AZ 11645373 is also available to selectively antagonize P2X7 
receptor, without effecting all the other P2X subtypes. It inhibits 
BzATP mediated calcium influx and ATP mediated IL1 release in 
vitro (Alcaraz et al.; 2003).  
Recently new allosteric modulator have been introduced: GW 791343 
hydrochloride is one of those already synthesized. This compound exhibits 
species-specific activity and acts as a negative allosteric modulator of 
human P2X7 and a positive allosteric modulator of rat P2X7 (Michel et al., 
2008a; Michel et a., 2008b). 
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1.2.2) Factors influencing P2X7 receptor expression 
 
P2X7 expression is modulated during macrophages differentiation and by 
treatment with cytokines (Hickman et al., 1994; Blanchard et al., 1991).   
P2X7 over-expression is also a consequence of INF-γ as well as Con-A or 
granulocyte macrophage colony-stimulating factor (GM-CSF) treatment 
(Blanchard et al.; 1991, Falzoni et al.; 1995, Lemaire et al.; 2011). 
Mutations in the COOH tail (i.e. Ala>Glu 496) cause loss of function.  
Macrophages bearing this mutation recover receptor function if treated 
with INF-γ (Gu et al.; 2001).   
 
 
1.2.2) P2X7 and cell cytoxicity 
 
In ‘90s it was suggested that P2X7 was involved in cytotoxic T-cell 
mediated cytotoxycity, using a perforine independent mechanism (Di 
Virgilio et al.; 1989, Filippini et al.; 1990, Di Virgilio et al.; 1990). 
Later, further studies showed that extracellular ATP via P2X7 was able to 
trigger killing of ingested bacillus Calmette Guérin (BCG) as well as of the 
phagocyte by apoptosis. Interestingly, apoptotic death of the phagocyte 
was required to kill the ingested pathogen, as if the phagocyte died by 
necrosis, ingested pathogens were quickly released and infected nearby 
cells (Molloy et al.; 1994).  
These intriguing findings implicating P2X7 in the elimination of 
intracellular parasites were later confirmed by Lammas and colleagues 
that further extended Molloy’s findings by pharmacologically modulating 
P2X7 receptor activity with oxidized-ATP or KN-62 (Lammas et al.; 1997). 
The peculiar mode of operation (as an ion channel and as a non-selective 
pore) of P2X7 has intrigued investigators even since this receptor was 
cloned. 
P2X7 is a non-desensitizing receptor, in that it remains open during the 
application of extracellular ATP, but quickly shuts as soon as ATP is 
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removed. This lack of desensitization generates a reversible plasma 
membrane pore that can be opened and closed simply by adding or 
removing ATP from the incubation medium.  In general, if the length of 
the permeabilization is limited to 10–15 min, macrophages recover after 
resealing and remain capable of performing physiological tasks, including 
phagocytosis. However, prolonged activation of P2X7 unavoidably leads to 
cell death (Di Virgilio et al.; 1990). This mechanism determines trans-
membrane ion fluxes, membrane depolarization and cellular swelling 
(Chiozzi et al.; 1997).  These changes lead to stimulation stress-
responding proteins (Adinolfi et al.; 2003) and caspases (1,3 and 8) 
(Ferrari et al.; 1999).  
Ion fluxes have a main role in P2X7 mediated cytotoxicity, as uncontrolled 
Na+ and Ca2+ entry trigger apoptotic or necrotic pathways, while K+ efflux 
is thought to be the main mechanism by which P2X7 drives pro-IL-1β 
processing. 
 
 
1.2.3)    P2X7 and Apoptosis 
 
We previously mentioned the role played by P2X7 in caspases activation. 
Caspases are very important proteins in cellular physiology for their key 
role in cell death and cytokine maturation. 
ATP was demonstrated to activate, via P2X7, cleavage of both pro- 
apoptotic caspases 3 and 8 (Ferrari et al.; 1999) through two different 
and independent pathways. 
Besides, ATP also triggers caspase-1 ICE (Interleukin-1 converting 
enzyme) activation, via P2X7.  
P2X7 also triggers fast activation of stress-activated protein kinase 
SAPK/JNK in a caspase-indipendent fashion (Humpreys et al.; 2000). 
SAPK triggers phosphorilation and transcription of factors, such as ATF2, 
Ets and c-Jun by means of phosphorilation in response to cell stress or 
cytokine stimulation.  
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1.2.4) P2X7 and cell growth  
 
Very recently it has been shown that P2X7 has an unsuspected role in cell 
growth. Human T lymphocytes express an ATP receptor/channel with 
properties akin to P2X7. It is activated by BzATP and inhibited by 
oxidized-ATP (oATP). Its activation caused Ca2+ influx and plasma 
membrane depolarization, but not large pore opening (Baricordi et al.; 
1996). Human B lymphocytes espress a receptor with these same 
properties. Paradoxically, in T lymphocytes, ATP as such has little if any 
growth-promoting effect and high concentrations (0.5–1 mM) are needed 
to trigger Ca2+ influx or plasma membrane depolarization. This 
observation was explained later by the finding that T lymphocytes 
continuously leak ATP, causing the desensitization of the P2X7-like 
receptor. Apyrase, an ATP-hydrolyzing enzyme, was sufficient to restore a 
near-normal sensitivity to ATP (Baricordi et al.; 1996). Thus, lymphocytes, 
like all other cell types, are continuously exposed to autocrine/paracrine 
stimulation by secreted ATP which likely reaches a much higher 
concentration in the pericellular space than in the bulk solution. 
It is well known that T lymphocytes do not proliferate unless mitogenically 
stimulated. Depending on the dose and incubation time, extracellular ATP 
has been reported to have diverse modulatory effects on mouse T 
lymphocytes, such as stimulation of DNA synthesis and blastogenesis (el-
Moatassim et al., 1989; Chused et al., 1996).  
On the contrary, in human T lymphocyte ATP has little or no proliferative 
activity, but rather behaves as a strong co-stimulus when added together 
with known mitogens such as phytohemoagglutinin (PHA) or anti-CD3 Abs 
(Baricordi et al.; 1996). Interestingly, mitogenic stimulation by any non-
nucleotide stimuli is strongly blocked by pre-incubation in the presence of 
oxidized ATP (oATP). Curiously, oxidized UTP is almost as potent an 
inhibitor as oATP, clearly indicating that different compounds able to form 
Schiff bases with plasma membrane receptors might be valuable as 
immunomodulators (Rhodes et al., 1996).  
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However, despite scattered evidence that human-resting non-neoplastic T 
lymphocytes express the P2X7 receptor but little P2Ys (Baricordi et al.; 
1996), the identity of the receptor mediating the growth-promoting effects 
of extracellular nucleotides in these cells remained largely unknown, till 
1999.  
To explore the possible contribution of the P2X7 receptor to growth 
stimulation Baricordi and colleagues investigated the effect of P2X7 
transfection in K562 (human erythroleukemia) and LG14 (B-
lymphoblastoid cell line) cells. Both cell lines lack endogenous P2X7 and 
P2Ys receptors. Interestingly, under normal culture conditions, 
proliferation rate of P2X7-transfected cells did not differ from that of 
mock-transfected cells; removal of serum did not affect P2X7-transfected 
cells proliferation rate while proliferation of mock-transfected cells was 
arrested (Baricordi et al.; 1999). Apyrase, on the other hand, inhibited 
P2X7 but not mock-transfectants growth, further supporting the role of an 
ATP-based autocrine/paracrine loop.  
Indirect evidence for the role of P2X7 in proliferation came from the 
finding that peripheral B lymphocytes from patients affected by the 
aggressive variant of chronic lymphocytic leukemia (CLL) express P2X7 to 
a level higher than patients with the indolent variant or healthy controls 
(Adinolfi et al.; 2002).  
In B-leukemic lymphocytes, P2X7 stimulation causes a large increase in 
intracellular Ca2+, while its blockade stops proliferation.  
These findings were later extended to HEK293 cells (Human Embryonic 
Kidney), a cell line lacking endogenous P2X7. Also, in this cell type, 
transfection of P2X7 conferred a growth advantage as in other model 
systems shown previously (Adinolfi et al.; 2005). 
In 2006, Bianco and co-workers provided an important and independent 
support to the growth-promoting activity of P2X7 by showing that 
proliferation of microglia cell clones and primary microglia was modulated 
by this receptor (Bianco et al.; 2006).  
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Microglia are resident cells of the brain that participate in reaction to 
traumas and in defense against foreign microorganisms. When exposed to 
bacterial products, microglia stop proliferating and differentiate into 
effector cells. During this process, microglia undergo a profound change of 
purinergic signalling involving a striking down-modulation of P2X7. This 
was rather a causal relationship because all treatments that selectively 
decrease P2X7 expression or function invariably decrease microglia 
proliferation. Furthermore, microglia cell clones lacking P2X7 are 
completely insensitive to the proliferation block caused by bacterial 
products (e.g. lipopolysaccharide).  
Thus, these experiments convincingly show that growth promoting activity 
is a feature of the native as well as recombinant P2X7 receptor. 
 
 
1.2.5) P2X7 and Cancer 
 
It is clear how important is to understand the molecular basis of P2X7 
“Janus behavior”, i.e. P2X7 ability to mediate cell death, on one hand, and 
cell survival and growth on the other. This is of particular relevance in 
view of recent evidence implicating P2X7 in cancer. During an 
investigation of the mechanism underlying P2X7-dependent growth 
promotion, it was observed that P2X7 transfection into lymphoblastoid or 
leukemic cell clones, in the absence of any additional stimulation, caused 
a small but significant increase in resting cytosolic Ca2+ ([Ca2+]i) levels 
(Baricordi et al.; 1999).  
This finding, together with the observation that P2X7-transfected cells had 
a thicker mitochondrial network (Adinolfi and Di Virgilio, unpublished 
observations), focused attention on the mitochondria , a crucial organelle 
for intracellular ion homeostasis and energy metabolism. 
Mitochondria have a key role in cell death, whether by necrosis or 
apoptosis (Giorgi et al.; 2008), thus it is not surprising that cytotoxicity 
due to P2X7 stimulation is preceded by mitochondrial swelling or even 
 
 
20 
 
disruption of the mitochondrial network (Mackenzie et al.; 2005, Adinolfi 
et al.; 2005).  
However, it is likely that this disruptive effect on mitochondrial physiology 
and morphology occurs only under extreme pathological conditions, while 
under more physiological conditions (i.e. no pharmacological stimulation 
by exogenous ATP), the P2X7–mitochondria liaison might be less 
catastrophic. Experiments performed with the mitochondrial potential 
probe TMRM showed that basal P2X7 activation may be not only harmless 
but even beneficial to mitochondria, as mitochondria of P2X7-transfected 
cells displayed a membrane potential 20–30 mV more negative than 
mock-transfected or wt control cells. The hyperpolarized mitochondrial 
potential was entirely dependent of P2X7 function as it returned to control 
values following addition of oATP or apyrase, or chelation of extracellular 
Ca2+ (Adinolfi et al.; 2005).  
Starting from these last observations, Ca2+ was hypothesized to be the 
messenger between P2X7 and mitochondria. 
There is a delicate relationship between Ca2+ and mitochondria: on one 
hand a higher mitochondrial potential enhances the electrochemical 
gradient for Ca2+ import into the mitochondrial matrix, and on the other, 
small increases in the mitochondrial Ca2+ concentration cause 
hyperpolarization (Jouaville et al.; 1999).  
Mitochondrial Ca2+ in P2X7-transfected cells turns out to be at least twice 
as high as in mock-transfected or wt cells, and also intra-mitochondrial 
Ca2+ transients triggered by activation of plasma membrane receptors are 
several-fold higher than in control cells. 
Higher intramitochondrial Ca2+ is fully dependent on influx across the 
plasma membrane as it reverts to normal level upon chelation of 
extracellular Ca2+ or addition of apyrase. 
Intramitochondrial Ca2+ level is tightly linked to energy metabolism. It 
was originally showen by Denton and McCormack that three key rate-
limiting enzymes in NADH synthesis and oxidative metabolism, pyruvate 
dehydrogenase, NAD+-isocitrate dehydrogenase and 2-oxoglutarate 
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dehydrogenase are modulated by Ca2+ (McCormack and Denton.; 1980), 
and that NADH production is accordingly increased by raising 
mitochondrial Ca2+.  
Altogether, hyperpolarized mitochondrial potential and higher NADH 
mitochondrial content, lead Di Virgilio and colleagues to put forward the 
obvious prediction that P2X7-transfected cells should have a more efficient 
oxidative phosphorylation and higher intracellular ATP content. Thus, they 
found that P2X7-transfected cells have a total cellular ATP content 
four- to six fold higher than wt or mock-transfected cells, as well as faster 
growth rate (Adinolfi et al.; 2005). 
This growth advantage depends on a strong increase in the efficiency of 
mitochondrial oxidative phosphorylation, an increased cellular ATP 
content, an improved ER Ca2+ handling, an increased activation of the 
transcription factor NFATc1 (Adinolfi et al.; 2005, Adinolfi et al.; 2009). 
P2X7-transfected cells have also an increased motility and a better ability 
to infiltrate soft agar and undergo metastatic dissemination in vivo 
(Adinolfi et al.; 2009, Jelassi  et al.; 2011). 
These features are very much reminiscent of those of cancer cells. 
The link between oxidative phosphorylation and cancer has always been 
ambiguous since the early observations of Otto Warburg (Warburg; 1956). 
Neoplastic phenotype has often been associated to alterations in 
mitochondria physiology and morphology, to the point that a defect in 
oxidative phosphorylation was considered a hallmark of cancer (Kim et al.; 
2006, Schulz et al.; 2006).  
Although there is no real indication that defective phosphorylation is an 
absolute feature of cancer cells, there is no doubt that many cancers 
display aerobic glycolysis. 
Glycolytic pathway is much less efficient than aerobic respiration (trough 
Krebs’ Cycle) as a source of ATP, nevertheless cancer cells may utilize 
glucose in such an efficient fashion to maintain more than adequate 
intracellular ATP levels (Kim et al.; 2006).  
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In any case, whether generated via aerobic respiration or glycolysis, ATP 
remains the key metabolic factor supporting cell growth. If, as shown by 
our findings, the P2X7 receptor increases cellular ATP stores and confers 
growth advantage, it might be expected that malignant tumours 
overexpress this receptor. 
So far, no extensive screening of P2X7 expression in malignant tumours 
has been performed; however, different laboratories have reported 
increased expression of this receptor in prostate (Slater et al.; 2004), 
breast and skin cancers (Slater et al.; 2004, Greig et al.; 2003), 
neuroblastoma (Raffaghello et al.; 2006), leukemia (Adinolfi et al.; 2002) 
and thyroid papillary carcinoma (Solini et al.; 2008). In most cases, these 
studies simply report histological evidence of receptor overexpression in 
tissue slices. No analysis of receptor function was performed.  
In a few studies, P2X7 function has been investigated in cell lines 
established from the primary tumours (Raffaghello et al; 2006, Solini et 
al; 2008).  
The interesting finding stemming from these more-detailed studies is that 
the P2X7 receptor in cancer may also support growth by indirect means, 
for example, by supporting secretion of growth factors. 
In human thyroid papillary carcinoma, P2X7 stimulation triggers release of 
IL-6, a growth factor for thyreocytes (Solini et al.; 2008), while in human 
neuroblastoma, this receptor supports release of substance P, a growth 
factor for these cancer cells (Raffaghello et al.; 2006).  
Neuroblastoma cells display an additional feature: although P2X7 is fully 
functional and induces formation of the “large conductance pore”, ATP has 
little of any cytotoxic effect, as neuroblastoma cells had learned to 
uncouple pore formation from the death-inducing pathway. This 
spectacular fashion could be criticized from two points of view, not 
dismissing one another: it could be as a “death escape” as a “boots to 
survive” mechanism, not yet well investigated. Looking at the first 
interpretation (“death escape”), it could be related to a defective 
activation of caspases, as neuroblastoma cells, in contrast to many other 
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non-tumour cell types, show no caspase-3 activation in response to P2X7 
stimulation.  Moreover, looking at the second interpretation (“boots to 
survive”), P2X7-mediated growth-promoting activity might provide a 
biological rationale for overexpression of this receptor in cancer as it 
would be odd, to say the least, if tumours overexpressed a potentially 
lethal receptor without any advantage for growth or survival.  
Then, several potential advantages for cancer cells, expressing P2X7, were 
hypothesized:  
• more efficient mitochondrial metabolism and ATP synthesis;  
• more active MAP kinase pathway;  
• increased ability to release growth- or survival-promoting factors 
• increased ability to release ATP, which may act as a growth factor 
itself, or stimulate release of additional factors.  
However, whether cancers really benefit of these potential advantages is, 
so far, purely speculative as the role of P2X7 in tumor growth and 
progression has never been investigated till now. 
Furthermore, while there is vast literature correlating the drop in 
mitochondrial potential with apoptosis or with an overall “reduced cellular 
fitness” under various experimental conditions, very few investigators 
have explored the link between hyperpolarized mitochondria and tumor 
growth.  
In 2002 and 2003 Damdimopoulos and Heerdt, respectively, reported 
their observation that mitochondria of cancer cells have an unusually high 
membrane potential (Damdimopoulos et al.; 2002, Heeredt et al.; 2003). 
More  recently Heerdt and colleagues confirmed and extended their own 
primary observation also in colonic cancer cells, one of the fastest-growing 
tumor in the body. 
Thanks to these works, a strong correlation was shown to exist between 
increased mitochondrial potential and  
• resistance to hypoxia  
• anchorage-independent growth  
• invasion of the basement membrane (Heerdt et al.; 2006).  
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The biochemical mechanism by which an increased mitochondrial potential 
allows better survival and growth is unknown, but Di Virgilio group’s 
finding that cells with hyperpolarized mitochondria accumulate higher 
cellular ATP stores may provide a reasonable physiological explanation as 
energy stores are a pre-requisite for any cell function. 
Finally, a crucial question is whether enough ATP accumulates in tumor 
interstitium to activate the low affinity P2X7 receptor.  
In fact, it is well known that in vitro P2X7 stimulation requires an ATP 
concentration of hundreds of micromolar, if not millimolar, levels that are 
supposed to be almost impossible to achieve in vivo.  
A recent study of ours showed, on the contrary, and rather surprisingly, 
that such high ATP levels, although unattainable within healthy tissues, 
may be reached in the tumour interstitium (Pellegatti et al.; 2008). 
A new role for extracellular ATP is recently planted in tumorigenic events 
and treatments.   
In fact, increase of extracellular ATP concentrations is supposed to 
improve the efficiency of antineoplastic chemotherapies (Michaud et al.; 
2011). It seems some successful chemotherapeutics can induce tumor cell 
stress and death by immunogenic stimulation. Dyeing tumor cells expose 
calreticulum (CTR) on the membrane surface as a consequence of 
endoplasmic reticulum stress, they can release chromatin-binding protein 
high mobility group B1 (HMGB1) in post-apoptotic phase and secrete ATP. 
CTR, HMGB1 and ATP are known to interact respectively with CD91, toll-
like receptor 4 (TLR4) and P2X7 receptor of dendritic cells (DCs). These 
interactions make presentation of tumor antigens and production of 
interleukin-1β. These two effects may determine immune system cells 
recruitment, on one hand, and the MHC formation on the other, 
implicating a Immune System itself involvement in tumor progression and 
depletion.   
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1.3) Cell metabolism in cancer – Warburg Effect 
 
In previous paragraphs we discussed the correlation between P2X7 
expression and tumorigenic characteristics, such as cellular growth (even 
in growth factors depletion), increased intracellular ATP contents in cancer 
cells, as well as an increased mitochondrial membrane hyper polarization, 
associated to a higher mitochondrial functionality. All this led us to 
hypothesized a direct effect of P2X7 expression and functionality on cell 
metabolism.  
Every kind of cell ménages its own energy trough mitochondrial 
respiration (oxidative phosphorylation). During this process cells convert 
one molecule of glucose in 36 molecule of ATP,  plus CO2 and H2O. 
On the contrary, glycolysis is the anaerobic catabolism of glucose, that is 
converted in lactate by LDH (Lactate De-Hydrogenise), when oxygen is 
depleted. It is rather so for example during an intense prolonged exercise 
in muscle as much as in tissues voted to fats metabolism (such as 
epatocytes and pancreatic cells). During this metabolic switch, one 
molecule of glucose generates 2 molecules of ATP.  
Glycolysis is also known as the Embden‐Meyerhof pathway, from the 
pioneering work of Gustav Embden & Otto Meyerhof, who through ‘20s 
and  ‘40s elucidated the complete glycolitic pathway.  
In 1924 Otto Warburg was the first to report that liver cancer cells 
compared to normal liver tissue, exhibited an increase in glycolytic activity 
in oxygen presence (Warburg and Negelein; 1924). In 1956 he showed 
that this characteristic metabolism did not exist only in solid tumors, but 
also in leukemia cells cultured in presence of oxygen (Warburg; 1956).  
These consistent observation led Warburg to hypothesize that such 
metabolic alteration in cancer cells was due to respiratory injury and was 
meant to be “the origin of cancer cells” (Warburg; 1956).  
Then, the assertion that cancer cells, originated from non-neoplastic cells, 
acquired a permanent respiratory defect that bypassed the Pasteur effect 
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(i.e. the inhibition of fermentation by oxygen) was called “Warburg Effect” 
(fig. 5).  
From that moment, looking at neoplastic alterations, a gradual and 
cumulative decrease in mitochondrial activity was commonly associated 
with malignant transformation.  
It is known that under aerobic condition, some tumor cells produce as 
much as 60% of their ATP trough glycolisis (Nakashima et al.; 1984).  
In conclusion, recent investigations into the mechanisms that underlie the 
Warburg effect may suggest that:  
• mitochondrial uncoupling can promote aerobic glycolysis in the 
absence of permanent and transmissible alterations to the oxidative 
capacity of cells  
• aerobic glycolysis may represent a shift to the oxidative metabolism 
of non-glucose carbon sources  
• mitochondrial uncoupling may be associated with increased 
resistance to chemotherapeutic insults (Samaudio et al.; 2009).  
The notes reported above highlighted the importance of understanding the 
mechanisms of mitochondrial uncoupling and their relation to metabolic 
alterations observed in cancer cells.          
More in details, glycolysis can be separated into two different phases: the 
first is the one requiring energy in the form of ATP, while the second is 
considered the energy‐yielding phase. In the first phase, 2 equivalents of 
ATP are used to convert glucose to fructose 1,6 - bisphosphate (F1 6BP). 
In the second phase F1,6BP is degraded to pyruvate, with the production 
of 4 equivalents of ATP and 2 equivalents of NADH (fig. 6).  
Pyruvate doesn’t proceed in Citric Acid Cycle (Krebs’ Cycle), but is then 
converted in lactate.  
A paradox was generated: why should a fast growing cell switch 
metabolism to follow the disadvantaged one (36 molecules of ATP vs 2 
molecules of ATP)? The most recent theory is based on the fact (actually 
under further investigations) that fast growing cells (i.e. cells 
characterized by a large number of mitosis) may need carbon subunits for 
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nucleotides, aminoacids and lipids synthesis. In fact, for example it is 
known that for Palminate synthesis (during fatty acids cycle) 7 molecules  
of ATP, 16 atoms of  carbon, 8 molecules of acetil-CoA  and 14 molecules 
of NADPH are request.      
Lactate surplus produced during aerobic glycolysis is released by the cells 
and contributes to create the characteristic acidification of tumor 
microenvironment, as well as ATP.  
Nowadays, even though Warburg effect molecular bases are not 
completely understood, detection of altered glucose uptake (and 
metabolism) in tissues is commonly used for diagnosis of cancer with 
Positron Emission Tomography (PET) (fig. 7). This technique uses a 
glucose analog (Fluor-Desox-Glucose, FDG), with a small radioactive 
molecule (18F, Fluor 18). FDG is injected trough vessels and it’s captured 
by tissues proportionally as they need. Tomography machine reveals 18F 
signal.  
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 Fig. 5. Warburg effect, schematic representation.  
  
 
 
 
 
Fig. 6. Schematic representation of glycolysis  
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Fig. 7. PET scan of body (right side),  
coupled with CT/TAC test (left side)  
 
 
 
1.4) Glucose deprivation and Warburg Effect 
 
Previously we pointed out how glycolysis works and how important 
glucose availability is for the cell. Glucose is the most important substrate 
used for generation of ATP or building blocks for nucleic acid, amino acid 
or lipid synthesis. Never the less, adaptation to limited nutrient supply is a 
key survival factor for normal and transformed cells  (Hanahan et al.; 
2011). This phenomenon involves complex biochemical and metabolic 
changes that affect ATP synthesis and production of intermediates needed 
for the synthesis of basic cell constituents (lipids and nucleic acid). 
Glucose deprivation triggers a complex adaptation response referred to as 
unfolded protein response (UPR) that involves mainly, but not exclusively, 
the endoplasmic reticulum (ER). UPR allows a profound re-shaping of 
cancer cell metabolism that increases survival, progression and resistance 
to chemiotherapics (Zhang et al; 2006).  
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The molecular basis of the better adaptation of tumours to low glucose is 
not clear, albeit several mechanisms have been invoked, such as a re-
programming of mitochondria, repression of the CC3/TIP30 gene, or down 
regulation of specific miRNA (e.g. miR-451) (Chen et al.; 2010, Haga et 
al.; 2010, Godlewiski et al.; 2010). 
In our opinion, tumour adaptation to low glucose intersects with the other 
burning aspect of cancer cell biology, the re-discovered (and yet 
described) Warburg effect.  
 
 
1.5) Activation of proteins,  involved in metabolism 
progression,  can act as check points.  
 
1.5.1) Glycolisis  enzymes. 
 
Aerobic glycolysis involves, and might be modulated by, changes in the 
expression of several enzymes of the glycolytic pathway, e,g, hexokinase 
(HK), phosphofructokinase (PFK), glyceraldehyde 3-phosphate (Ga3P), 
pyruvate kinase-M2 (PK-M2), as well as enzymes specifically controlling 
pyruvate entry into the Krebs cycle such as pyruvate dehydrogenase 
kinase (PDHK) (Annibaldi et al.; 2010).  
If and how these enzymes are also modulated in conditions of limited 
glucose availability is actually under investigation. 
As we reported before, glucose deprivation is known to activate 
oncogenes. These can upregulate proteins involved in aerobic glycolysis. 
In turn, proteins implicated in increased glycolysis can make tumor cells 
more resistant to apoptosis. Aerobic glycolysis is known to induce 
acidification of the tumor environment, favoring the development of a 
more aggressive and invasive phenotype (Hanahan et al.; 2000). This 
phenomenon could be due to the lactate release. 
Altering the pH around tumors might represent a way to hamper tumor 
development as suggested by a recent work demonstrating that 
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bicarbonate, which increases the pH of tumors, prevented spontaneous 
metastatization (Robey et al.; 2009). 
 
 
1.5.2) Glucose transporters. 
 
Glucose is imported into the cells trough glucose transporters (Kasahara 
and Hinkle; 1977, Koivisto et al.; 1991). Glucose transporters are four 
(GLUT-1, GLUT-2, GLUT-3 and GLUT-4), with different affinity, but only 
two of them have the highest once: GLUT-1 (1.3 mM) and GLUT-4 (5.6 
mM). GLUT-4 is the one involved in accumulating intracellular stores 
(Koivisto et al.; 1991), in fact it is shown to be activated by insulin 
receptor during metabolic diseases (i.e. diabetes), mediating a  slow 
exocytosis and fast endocytosis (Satoh et al, 1993; Li et al, 2001).  
On the contrary, GLUT-1 is the one mediating direct and ready to use 
glucose transport (Bucci et al.; 2011). It is ubiquitous because it provides 
the basal glucose uptake, not insulin dependent.  
Moreover GLUT-1 is highly expressed in erythrocytes and brain (Mueckler 
et al, 1994).  
Recent evidences show GLUT-1 over-expressed also in fast growing and 
neoplastic tissues (Airley et al.; 2001, Brown et al.; 2006).  
Studies with cultured mammalian cells support the item that glucose 
regulates its own transport and metabolism as evidenced by increasing 
glucose uptake, in response to glucose starvation in fibroblasts 
(Germinario et al.; 1984, Ullrey et al.; 1975, Yamada et al.; 1982), 
cardiocytes (Paris et al.; 1980), adipocytes (van Putten et al.; 1985), glial 
(Walker et al.; 1988) and muscle (Walker et al.; 1989) cells.   
More recently other glucose transporters have been characterized: EST 
(Expressed Sequence Tag) database catalogued them in classes II and III 
Transporters, concerning to homologies into the sequence (Maier et al.; 
2002).  
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Class II transporters are mainly expressed by the luminal membrane of 
small intestine epithelial cells and also present at lower levels in other 
tissues, such as kidney, brain, fat, testis, and muscle (Burant et al, 1992; 
Shepherd et al, 1992; Concha et al, 1997), small intestine and colon (Li et 
al, 2004), leukocytes, testis, and sperm (Phay et al, 2000; 
Carayannopoulos et al, 2004; Kim and Moley, 2007), pancreas, kidney, 
and placenta and, to a lower extent, in heart and slow-twitch skeletal 
muscle, particularly in intracellular structures (Doege et al, 2001b; 
Scheepers et al, 2004). Some of them are specific for fructose, instead of 
glucose. 
Class III transporters are structurally different from the others (Scheepers 
et al, 2004) and are mainly glucose transporters. 
 
 
1.5.3) Activation of PI3K/Akt pathway supports cell 
proliferation in cancer. 
 
One more protein over-expressed and more functional in tumors  is Serin-
Treonin kinase Akt/PKB. Originally it was identified in mammalian as viral 
oncogen v-Akt omologue and was demonstrated to induce leukaemia in 
mouse (Bellacosa et al.; 2005). Akt is known to be directly activated by 
PI3K (Phosphoinositide 3-kinase), in response to stress (Borgatti et al.; 
2003), but other pathways are nowadays thought to induce Akt activation 
independently by PI3K. At the moment all these alternative paths are 
under further investigation. 
In classical pathway, the one involving PI3K, after stimulation of 
membrane receptors (such as grow factor receptor, insulin receptor) 
induces conversion of membrane PIP2 (phosphoinositide 2 phosphate) in 
PIP3 ( phosphoinositide 3 phosphate) by PI3K. Akt captures PIP3  in its PH 
domain and moves to the membrane where subsequent phosphorilations 
activate kinase activity of Akt , i.e. Akt is able to activate other effectors 
(fig. 8).   
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Maximal activation of kinase Akt runs through self-phosphorilation in 
Serin473 and Treonin308 (Delcommenne et al.; 1998, Shaw et al.; 1998, 
Toker and Newton; 2000, Laine et al.; 2000).  
Once activated, Akt can also move into the nucleus and prime other 
nuclear proteins as well as transcription factors (Borgatti et al.; 2003). 
It was demonstrated that a membrane stimulation can cause several  
falls-reactions that can modify nuclear lipids metabolism (Michell et al.; 
1992, Divecha et al;1993, Martelli  et al.; 1999). 
Activation of PI3K/Akt pathway has been correlated with a lot of cellular 
critical events, like proliferation, apoptosis regulation, energetic 
metabolism, esocytosis and endocytosis, adhesion, vesicle traffic and 
cytoskeleton regulation ( Martini et al.; 1998, Fruman et al; 1998, Neri et 
al.; 2002).  
Apoptosis resistance, in hypoxia, was directly correlated to PI3K/Akt 
activation because of direct activation of GSK-3β (Glycogen Synthase 
Kinase 3-β ) (Risbud et al.; 2005), REDD1 factor over-expression 
(Schwarzer et al.; 2005) and transcription factors HIF1α and p300 
modulation (Ardyanto et al.; 2006).  
Nevertheless, PI3K/Akt activation is commonly associated to tumorigenic 
transformation, metastatic events and drugs resistance in chemotherapy 
(Neri et al.; 2002).   
More recently, Akt was suggested as regulator of metabolism and 
progression of tumors (Krzeslak; 2010), while the whole PI3K/Akt/mTOR 
pathway was supposed to became a therapeutic target for neuroblastoma 
disease (Fulda et al.; 2009) and leukaemia (Martelli t al.; 2010). 
In 2004 Jacques-Silva and colleagues started to investigate if there was a 
direct connection between  P2X7 and Akt activation in astrocytes 
(Jacques-Silva et al.; 2004). 
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Fig. 8. Schematic representation of PI3K/Akt pathway 
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2) Aim of the study 
 
It has been demonstrated that Purinergic receptor P2X7 play an important 
role in modulating important physiological cellular activity. 
We reported evidence according to which P2X7 regulates survival and cell 
growth as well as cell death and apoptosis. 
We underlined how important its main ligand (ATP) is in modulating P2X7 
functionality. Moreover we reported modification occurring to mitochondria 
when P2X7 is expressed.  
P2X7 over-expression was related to tumor progression and aggressive 
phenotype. 
We analysed glycolysis and its modification in cancer cells, but also how 
important is glucose deprivation in forcing tumorigenesis and, perhaps, 
metabolism switch.  
 
Aim of the present study is: 
 
• Verify the effect of P2X7 on cellular metabolism under conditions of 
limited nutrient supply; 
• Investigate the possible role of P2X7 in the Warburg Effect; 
• Unveil the pathway responsible for Warburg Effect in P2X7-
expression cells; 
• Hypothesise a possible role for P2X7 receptor as pharmacological 
target for tumors treatments.  
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3) Materials and Methods 
 
3.1) Cells maintenance 
 
HEK293 cells were cultured in DME/F-12 1:1 medium (Sigma, St. Louis, 
MO) containing 15% heat-inactivated FCS (Life Technologies, Paisley, 
Scotland), 100 U/ml penicillin, and 100 μg/ml streptomycin. Stable clones 
were cultured in the same medium containing G418 sulfate (Geneticin; 
Calbiochem, La Jolla, CA) at a concentration of 0.2 mg/ml. Visualization of 
transfected cells was performed in a saline solution (standard saline 
solution) containing 125 mM NaCl, 5 mM KCl, 1 mM MgSO4,1 mM 
Na2HPO4, 5.5 mM glucose, 5 mM NaHCO3, 1 mM CaCl2, and 20 mM 
HEPES (pH 7.4). 
ACN neuroblastoma cells were maintained in RPMI (Celbio EuroClone) 
supplemented with 10% fetal calf serum, 100 U/ml penicillin and 
100μg/ml streptomycin (all from Celbio EuroClone) and 1% non-essential 
amino acids (GIBCO, Life Technologies, Paisley, Scotland). Cells were 
detached with the Cell dissociation solution (Sigma-Aldrich). Cells were 
plated in 75cm2 Falcon flasks (Microtec, Naples, Italy) and incubated at 
37C in humidified incubator in the presence of 5% CO2. 
  
3.2) Transfection of HEK293 Cells and Selection of Stable Clones 
 
HEK293 wt cells were transfected with calcium phosphate. Briefly, the first 
day, 2.5 × 106 HEK293 cells were plated in Petri dishes. The second day, 
for each dish, 30 μg of plasmid DNA was resuspended in a total volume of 
450 μl TE (10 mM Tris, 1 mM EDTA, pH 8) and then 50 μl of a 2.5 M CaCl2 
solution was added. This solution was added dropwise under vortexing to 
a tube containing 500 μl of 2× HBS (280 mM NaCl, 50 mM HEPES, 1 mM 
Na2HPO4, pH 7.12, at 25°C). After a 30-min incubation at room 
temperature, the DNA precipitate was added to the dish dropwise. The 
third day medium was changed. The fourth day, G418, 0.8 mg/ml, was 
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added to fresh medium to select transfected clones. After clone selection, 
the selective medium contained G418, 0.2 mg/ml. 
Transient transfection was performed using the same procedure directly 
on coverslips for 0.5 × 106 cells, 4–8 μg of plasmid DNA in a total volume 
of 90 μl TE, 10 μl of CaCl2 solution, and 100 μl of 2× HBS. The plasmid 
containing rat P2X7-GFP in pcDNA3 used for stable transfection was kindly 
provided by Dr. Annemarie Surprenant (University of Sheffield, UK). 
 
3.3) Cell lines and proliferation assay. 
 
For cell proliferation assay, 5 x 104 cells/well were plated in Falcon multi-
well plates over night with completed media. 
The morning after media was changed and serum starvation and glucose 
depletion started. That was the zero point (T0).  
Cells were counted at  T0 and every 24h (to 48 hours) from media 
changing.  
 
3.4) Treatments and drugs. 
 
All experiments were performed in the absence of serum (e.g. serum-free 
DMEM or serum-free RPMI media). Low glucose experiments were 
performed in the presence of 4 mM glucose (low-glucose-DMEM or low-
glucose RPMI, from Sigma-Aldrich or CellbioEuroclone, respectively). Cells 
were plated overnight in complete medium, then this medium was 
replaced with serum- or serum/glucose-free medium for the next 4 hours. 
ATP (Roche, Milan, Italy) was used at a concentration of 1 mM, FCCP 
(Sigma-Aldrich) was used at a concentration of 250 nM, the P2X7R 
inhibitor A 740003 (Tocris Bioscience, Ellisville, MS, USA) was used at a 
concentration of 200 μM. Mitochondria were stained with the potential-
insensitive green stain Mito Traker Green (Invitrogen Italia, Milan, Italy), 
and the potential-sensitive red stain Tetramethyl rhodamine methyl ester 
(TMRM, Invitrogen). TMRM was stored as a 10 mM stock solution in 
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ethanol, while Mito Traker Green was stored as a 100nM stock solution in 
DMSO (Sigma-Aldrich).  
 
3.5) Measurement of intracellular ATP 
 
Intracellular ATP levels were measured by luminometric assay using the 
Enliten ATP assay system (Promega). 15 x 103 cells/sample were lysed 
with 10 μl lysis buffer (FireZyme, San Diego, USA), and supplemented 
with 90 μl of diluent buffer (FireZyme) to stabilize ATP. Samples were 
then placed in a Victor 3 multilabel counter (Perkin Elmer) equipped with a 
Wallac liquid injector (Perkin Elmer) that allowed rapid injection of the 
luciferin-luciferase solution (100 μl).  
 
3.6) Lactate measurement 
25 x 103 cells/well were plated in the different media as described above. 
Supernatants were withdrawn at the various time-points and lactate 
release was measured with a Lactate Colorimetric Assay Kit (Abcam, 
Cambridge, UK), according to manufacturer’ s indication.  
 
3.7) Real-Time PCR 
Real-time PCR was performed in a Step One Real-Time PCR system 
(Applied Biosystems). 106 cells/well were plated under the different 
experim ental conditions. Total RNA was extracted with TRIZOL reagent 
(Invitrogen, Paisley, Scotland). Reverse transcription was performed 
starting from 1 μg of total RNA/well, with the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems) as described by the manufacturer. 
Two microliters of cDNA were used as template. Amplification was 
performed with custom-made primers and Taqman probes (Applied 
Biosystems) as detailed below, and with an internal P2Y1 reference (Pre 
developed Taq Man assay reagents, Applied Biosystems). A comparative 
CT analysis (ΔΔCT) was done to allow determination of the change of 
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expression (fold increase) of the target cDNA in the experimental samples 
relative to the reference sample. 
 
3.8) Western Blot Analysis.   
Cells were plated at the concentration of 5 x 105 per well. Proteins were 
extracted in ice-cold, Ca2- free, lysis buffer containing 
phenylmethylsulfonyl fluoride (PMSF, 1 mM), benzamidine (1 mM) and 
0,1% Triton (all by Sigma-Aldrich), processed and blotted as described 
previously (Adinolfi et al.; 2002). Membranes were incubated with the 
primary mAbs overnight at 4° C. The following mAbs were used: anti-
PKM2, anti-PDHK1, anti-Glut1, anti-Ph-Akt/PKB (Ser473) and anti-
Akt/PKB (all from Cell Signaling, Milan, Italy), at a dilution of 1:1000 in 
TBS-t buffer (TBS with 0.1% Tween 20) supplemented with 1% BSA. An 
anti-actin mAb, diluted 1:500 (Sigma-Aldrich), was used as loading 
control. Then membranes were incubated with a secondary goat anti-
rabbit, HRP conjugated antibody (Bio-Rad, Kobenhavn, Denmark) diluted 
1:3000 in TBS-t buffer. Bands were visualized by enhanced 
chemiluminescence detection kit (Amersham, GE Healthcare, Milan, Italy). 
Densitometric analysis of the protein bands was carried out with the Alpha 
VIEW program (Alpha Innotech Corporation, San Leandro, CA). Band 
densitometry was normalized on the actin ratio.  
 
3.9) Visualization of mitochondria and semi-quantitative 
evaluation of mitochondrial potential 
Cells, plated onto 24-mm glass coverslips, were loaded with 1μM 
Mitotracker-green and 20 nM TMRM in the different culture media for 30 
min at 37°C. At the concentration used, TMRM is mainly localized in the 
mitochondria emitting a level of fluorescence proportional to the absolute 
value of  mitochondrial potential (Adinolfi et al.; 2005). Confocal images 
were acquired with a Zeiss LSM 510 confocal microscope equipped with a 
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plan-apochromat 63x oil immersion objective (Carl Zeiss, Oberkochen, 
Germany) as previously described  (Adinolfi et al.; 2005). 
 
3.10) Glycogen store detection 
Cells, 25 x 103, were plated overnight in Polylisin 1X-coated, UV sterilized- 
24-well plates were pre-treated. Glycogen was revealed with PAS (Periodic 
Acid-Schiff) Kit (Sigma-Aldrich). Cells were fixed with methanol 96% 
(Sigma-Aldrich) and processed as suggested by the manufacturer. 
 
3.11) Data analysis.  
All data are shown as mean ± sd. Tests of significance were performed by 
Student’s t test using GraphPad InStat software (GraphPad, San Diego, 
CA, USA).  
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4) Results  
 
4.1) Growth promotion effect of P2X7 in serum and glucose 
deprivation 
 
We have previously shown that under conditions of limited nutrient supply 
(i.e. serum starvation), expression of the P2X7R confers a strong growth 
advantage to various human cell lines (Baricordi et al.; 1999, Adinolfi et 
al.; 2005).  
The trophic effect of P2X7 is at least partially mediated by an increased 
efficiency of Ca2+ handling by the ER, an improved oxidative 
phosphorylation and a strong activation of the transcription factor NFATc1 
(Adinolfi et al.;2005, Adinolfi et al.;2009). This suggests that P2X7 
increases cell adaptation to unfavourable environmental conditions. 
Glucose starvation, an additional condition of reduced nutrient supply 
often occurring in several physiological or pathological states, triggers a 
complex array of adaptive responses involving a thorough reprogramming 
of metabolic pathways, and often culminating in the UPR (Mori et al.; 
2000).  
Figure 9A shows that growth of HEK293-P2X7 cells proceeded unimpeded 
in serum-free, low glucose medium, while on the contrary proliferation of 
HEK293-mock cells was fully abrogated. The mechanistic basis of the 
growth-promoting effect of the P2X7R are not fully understood, however 
we have shown that an improved energy metabolism is likely to play an 
important role as P2X7R expression increases mitochondrial potential and 
improves mitochondrial ATP synthesis (Adinolfi et al.;2005).  
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4.2) ATP production in HEK293, transfected with P2X7R, 
decreases during glucose depletion 
 
Figure 9B shows that an improved energy metabolism is a feature of 
HEK293-P2X7 cells in low glucose, as total cellular ATP content under this 
condition of extreme nutrient deprivation is almost two fold higher than in 
HEK293-mock cells. However, low glucose affected ATP synthesis of 
P2X7R-lacking to a larger extent than that of P2X7R-expressing cells, as 
physiological/low glucose ATP ratio dropped from 2.4 to 1.6 in HEK293-
P2X7 and HEK293-mock respectively. This finding was surprising since, 
due to a more efficient mitochondrial metabolism of HEK293-P2X7 
compared to HEK293-mock (Adinolfi et al.; 2005), we anticipated that ATP 
synthesis in HEK293-P2X7 cells should be less sensitive to glucose 
deprivation.  
 
4.3) Lactate release in HEK293, transfected with P2X7R, 
increases during glucose depletion 
 
In order to assess the relative contributions of glycolysis and oxidative 
phosphorylation to ATP synthesis in the presence or absence of P2X7R, we 
measured lactate generation in physiological and low glucose.  
As shown in Figure 9C, in physiological glucose HEK293-P2X7 cells 
released about twice as much lactate as HEK293-mock cells. 
Lowering glucose medium strongly increased lactate output in both 
HEK293-P2X7 (from 0.285 to 0.756 nmoles/L/ug protein) and HEK293-
mock (from 0.183 to 0.388 nmoles/L/ug protein).  
Increase in lactate output caused by incubation in low glucose was larger 
in HEK293-P2X7 than in HEK293-mock as the low glucose/physiological 
glucose lactate output ratio was 2.65 and 1.91 for HEK293-P2X7 and 
HEK293-mock, respectively. This experiment gives two relevant pieces of 
information:  a) basal P2X7R expression per se increases lactate output, 
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and b) HEK293-P2X7 cells produce more lactate in response to nutrient 
starvation. 
 
 
4.4) Stimulation of P2X7R mediates lactate release increase 
in HEK293 
  
Mitochondrial uncoupling is one of the most potent stimuli for lactate 
production (Samudio et al.; 2009). Pharmacological stimulation of P2X7R 
by exogenous ATP causes Ca2+ overload of mitochondria, mitochondrial 
potential collapse and uncoupling  (Adinolfi et al.;2005).  
Thus, we tested the effect of stimulation with extracellular ATP on lactate 
output. Figure 10 shows that ATP is a powerful stimulus for lactate 
production, whether in physiological or low glucose, but only in HEK293-
P2X7 cells, as expected. To validate the effect of exogenous ATP we tested 
the mitochondrial uncoupler FCCP which triggered a large lactate 
production, in physiological as well as low glucose. Very interestingly, 
lactate stimulation by carbonylcyanide p-trifluoromethoxyphenylhydrazone 
(FCCP) was dependent on the presence of P2X7R. 
Experiments described so far were performed by expressing P2X7R in cells 
that do not normally express this receptor. 
Fig. 9. P2X7R expression stimulates cell metabolism. HEK293-P2X7 (open bars) and 
HEK293-mock cells (closed bars) were incubated in 17mM- or 4mM glucose-
supplemented medium, and cell proliferation (panel A), intracellular ATP content 
(panel B) and lactate output (panel C) were measured as described in Materials and 
methods. Intracellular ATP and lactate output were assessed after a 24 h incubation 
under the different experimental conditions. Data are averages + SD of multiple 
determinations (n = 9 for ATP measurements; n = 12 for lactate measurements). 
Statistical significance, * p < 0.05; ** p < 0.03.  
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4.5) Blockade of P2X7R mediates lactate release decrease in 
ACN neuroblastoma cells 
 
To check if the native P2X7 receptor has a similar effect on lactate output 
we turned to the human neuroblastoma ACN, a cell line previously 
characterized for P2X7 expression in our laboratory (Raffaghello et al.; 
2006). As shown in Figure 11, lactate production by ACN cells was 
stimulated by exogenous ATP, and was abrogated by the selective P2X7 
blocker A740003.  
These results suggest that P2X7R is able to modulate glycolytic 
metabolism under different conditions: a) basal conditions, b) upon 
stimulation with extracellular ATP, and c) in the presence of uncoupled 
mitochondria. We then set to identify the mechanisms involved. 
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 Fig. 10. P2X7 expression is needed for ATP or FCCP-stimulated lactate output. HEK293-
P2X7 (open bars) and HEK293-mock cells (closed bars) were incubated in 17mM- or 4mM 
glucose-supplemented medium for 24 h in the absence or presence of either ATP or FCCP. 
Data are averages + SD of multiple determinations (n = 3). Statistical significance, * p < 
0.05; ** p<0.03. 
 
 
47 
 
 
Fig. 11.  Lactate release is dependent upon P2X7 stimulation in the human neuroblastoma 
ACN cell line. 25 x 103 ACN cells/well were plated in high (11 mM) (open bar) or low (4 
mM) (closed bar) glucose medium and lactate release measured after a 24 h incubation in 
the absence or presence of either ATP or the selective P2X7 blocker A740003. Data are 
averages + SD of multiple determinations (n = 3). Statistical significance, * p < 0.05; ** 
p<0.03.    
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4.6) G3PDH is up-regulated in HEK293 during glucose 
depletion 
 
A key enzyme controlling glycolysis is glutheraldehyde 3-phosphate 
dehydogenase (G3PDH) which catalyzes specifically catalyzes 
phosphorylation and oxidation of glyceraldehydes-3-phosphate to 1,3-
bisphosphoglycerate in the glycolytic cascade.  
The G3PDH gene is up-regulated following stimulation of glycolytic 
metabolism, especially in cancer cells (Altenberg et al.;2004).  
Figure 12A shows that G3PDH levels are over 3-fold higher in HEK293-
P2X7 versus HEK293-mock cells in physiological glucose. In low glucose 
G3PDH expression increases further in both cell types, but much to a 
much larger extent in HEK293-P2X7 than in HEK293-mock cells, thus 
raising the fold increase to 4.60. Two other key check-point enzymes in 
glycolysis often upregulated in cancer cells are pyruvate kinase M2 (PK-
M2) and pyruvate dehydrogenase kinase1 (PDHK1) (Vander Heiden et al.; 
2009).  
 
4.7) PK-M2 expression is enhanced in HEK293 during glucose 
depletion 
 
Figure 12B shows that in low glucose level of expression and 
phosphorylation of PK-M2 is enhanced in HEK293-P2X7 compared to 
HEK293-mock cells.  
PK-M2 generates pyruvate from phosphoenol-pyruvate and preferentially 
poises pyruvate for degradation to lactate, minimizing its transfer to the 
mitochondria.  
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4.8) PDHK1 is more activated in HEK293 during glucose 
depletion 
 
PDHK1 phosphorylates and thus inactivates pyruvate dehydrogenase, the 
key enzyme controlling pyruvate entry into Krebs cycle. The net effect of 
PK-M2 and PDHK up-regulation will thus be an inhibition of mitochondrial 
functions and a preferential diversion of pyruvate to lactate. In low glucose 
condition PDHK1 was also overexpressed in HEK293-P2X7 cells (fig. 12C). 
Fig. 12.  P2X7 expression causes overexpression of the key glycolytic enzymes 
G3PDH, PK-M2, and PDHK1. HEK293-P2X7 (open bars) and HEK293-mock cells 
(closed bars) were incubated in 17mM- or 4mM glucose-supplemented medium, and 
G3PDH, PK-M2 and PDHK1 expression were measured by quantitative PCR (G3PDH, 
panel A) or Western blot (PK-M2 and PDHK1, panels B and C). G3PDH mRNA content 
is expressed as a RQ ratio normalized onto P2Y1 mRNA. Protein bands in panels B 
and C were quantified by densitometry and normalized onto endogenous actin band. 
Statistical significance , * p < 0.05; ** p<0.03. 
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4.9) Glucose depletion causes mitochondria depolarization 
and swelling in HEK293  
 
To verify this hypothesis we performed a semi-quantitative assay of 
mitochondrial function in vitro using two selective fluorescent 
mitochondrial probes: Mito Tracker green and TMRM.  
Mito Tracker green accumulates into the mitochondria in potential-
insensitive fashion, thus allowing a precise morphological identification of 
these organelles independently of their energy charge. On the contrary, 
TMRM is a potential-sensitive dye that localizes to the mitochondria in a 
mitochondrial potential sensitive fashion, and thus allows to measure the 
energy state of mitochondria.  
Figure 13, A and B, shows that, in agreement with our previous findings 
(Adinolfi et al.; 2005), HEK293-P2X7 cells show a larger TMRM uptake, to 
witness higher mitochondrial potential, compared to HEK293-mock. In low 
glucose mitochondrial potential of HEK293-P2X7 dropped to about the 
same level as that of HEK293-mock, indicating that glucose deprivation 
inhibited mitochondrial function. 
Mito Tracker green staining shows that in physiological glucose 
mitochondria of HEK293-P2X7 cells were thicker and swollen, while those 
of HEK293-mock were organized in the typical ramified network.  
In low glucose, alongside with the collapse of mitochondrial potential, we 
also observed fragmentation of the filamentous mitochondrial network in 
both cell types, an indication of mitochondrial injury.  
 
 
 
 
 
 
 
 
Fig. 13.  Glucose depletion causes a decrease in mitochondrial potential.  HEK293-P2X7 (A) 
and HEK293-mock (B) cells were incubated under the different conditions for 24 h, and at 
the end of this incubation were labeled with TMRM (panels a and d)  and Mito-Traker Green 
(panels b and e). Image acquisition and analysis were performed as described in Materials 
and methods. Panels c and f show merge of the red and green channels. 
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Fig. 13 
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4.10) Glucose depletion increases glucose uptake by 
enhancing GLUT-1 transporter expression in HEK293 
 
These data indicating a shut-off of mitochondrial energy metabolism in 
low glucose suggest that under nutrient deprivation HEK293 cells should 
increase their ability to use glucose, and thus improve glucose uptake.  
The main membrane carrier responsible for non-insulin-dependent glucose 
uptake is Glut-1.  
Figure 14 shows that HEK293-P2X7 cells had a higher level of expression 
of Glut-1 both in physiological and low glucose. This suggests that 
HEK293-P2X7 cells may adapt to low nutrient conditions by up-regulating 
expression of glucose carrier thus maximizing nutrient uptake.  
However, it has been recently reported that glucose deprivation also 
increases use of intracellular glycogen stores in tumour cells (Kang et al.; 
2009).  
 
4.11) HEK293 cells use intracellular glycogen stores to 
support glycolysis during glucose depletion 
 
Therefore we checked whether HEK293 cells might also compensate 
reduced glucose supply by degrading intracellular glycogen.  
As shown in Figure 15, glycogen stores were higher in HEK293-P2X7 than 
in HEK293-mock cells. Incubation in low glucose medium caused a fast 
depletion of glycogen stores, thus presumably providing glucose for 
glycolysis and lactate generation. Therefore, P2X7R expression allows cells 
to exploit multiple sources of glucose, exogenous and endogenous, to 
support glycolytic metabolism.  
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Fig. 14.  Glucose depletion causes up-regulation of Glut-1 in HEK293-P2X7 but not in 
HEK293-mock cells. Samples were processed as described in Materials and methods  and 
protein bands were quantified by densitometry and normalized onto endogenous actin 
band. HEK293-P2X7, open bars; HEK293-mock, closed bars. One experiment representative 
of four similar is shown. 
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Fig. 15.  HEK293-P2X7 cells possess larger glycogen stores than in HEK293-mock cells. 
HEK293-P2X7 (panels and b) and HEK293-mock (panels c and d) were plated in 24 
well/plates and incubated under the different experimental conditions as described in 
Materials and methods. After 24 h they were PAS-stained and analyzed by phase contrast 
microscopy. Glycogen deposits are revealed by the pink stain. Pictures were taken with an 
Olympus IMT - 2 phase – contrast microscope equipped with a 40X objective (Olympus Life 
Science Europe, Munich, Germany)., geared with a DS-2Mv high-speed colour camera 
(Nikon, Tokyo, Japan). For each experimental condition, 3 wells per plate were analysed. 
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4.12) Serine/Threonine Kinase Akt is more expressed and 
phosphorylated in HEK293 
 
Over the last few years it has become clear that one of the main factors 
controlling glucose uptake, glycolysis, lactate production and cell 
proliferation is the serine/threonine kinase Akt/PKB (Plas et al.; 2001, 
Ratmell et al.; 2003). This kinase is potentially relevant in the context of 
purinergic modulation of energy metabolism because recent reports show 
that P2X7R modulates its activity  (Jaques-Silva et al.; 2004, Gomez-
Villafuertes et al.; 2009).  
Figure 16 shows that Akt/PKB is expressed to about the same level in both 
HEK293-P2X7 and in HEK293-mock cells, and that more importantly, 
while in HEK293-mock cells Akt/PKB is dephosphorylated in the key 
Ser473 residue, and thus inactive, in HEK293-P2X7 cells Akt/PKB is 
phosphorylated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16.  Akt/PKB is phosphorylated in HEK293-P2X7 but not in HEK293-mock cells. 
HEK293-P2X7 (open bars) and HEK293-mock cells (closed bars) were incubated for 24 h 
under the different experimental conditions and processed as detailed in Materials and 
methods. Protein bands were  
quantified by densitometry and normalized onto endogenous actin band. One experiment 
representative of six similar is shown. 
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5) Discussion and Conclusions 
 
Extracellular environment is a key factor determining cell growth and 
differentiation. It is a fact that extracellular matrix and tissue biochemical 
milieu profoundly affect proliferation, motility, cell differentiation and 
death (Rozario et al.; 2010).  
Cells that are better equipped to exploit the extracellular nutrient supply 
gain an undisputable growth advantage on other cells. This also implies 
being less dependent on the nutrient concentration of the medium. It is a 
fact that cancer cells grow in the presence of much lower serum 
concentrations as well as in the presence of lower glucose levels than 
normal cells (Hanhan and Weinberg; 2000).  
These changes are probably the consequence of the selective pressure 
imposed by the fluctuating levels of nutrients within solid tumours and it is 
clear that they will provide a strong selective advantage over normal cells. 
Ability of cancer (but in general of all fast-growing) cells to conserve a 
strong glycolytic activity during normoxia and in the presence of often 
fully functional mitochondria (the “Warburg effect”) is probably the result 
of the pressure placed on cancer cells to maximize the use of all possible 
sources for energy metabolism and structural synthetic processes 
(Samudio et al.; 2009). 
In fact, intermediate metabolites generated during glucose degradation to 
pyruvate are also used for DNA, aminoacid and lipid synthesys. It is 
intuitive that fast-growing cells need to generate an adequate amount of 
high-energy intermediate (ATP) as well as a sufficient provision of  
building blocks for structural synthesis. This process may be endangered if 
nutrient supply is drastically reduced, as it happens in the core of solid 
tumours, despite the angiogenic activity induced by the tumour itself or by 
infiltrating inflammatory cells. 
P2X7 is a receptor mainly expressed by inflammatory and immune cells 
(Di Virgilio et al.; 2001). 
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However, more recent data show that it is also upregulated in several 
cancers, such as acute and chronic lymphocytic leukemia, acute myeloid 
leukemia, prostate carcinoma, breast cancer, neuroblastoma, thyroid 
papillary carcinoma  (Adinolfi et al.; 2002, Chong et al.; 2010, slater et 
al.; 2004, Raffaghello et al.; 2006, Solini et al.; 2008). 
The biological meaning of P2X7 upregulation in tumours is unknown, but it 
has lead to the operational proposal to use pharmacological P2X7 agonists 
to kill cancer cells, as it is well known that this receptor is a potent inducer 
of cell death when overstimulated. A few years ago we showed that in 
human leukemic lymphocytes and in human neuroblastoma cells the 
P2X7R is uncoupled from apoptosis, and rather sustains growth (Adinolfi 
et al.; 2002, Raffaghello et al.; 2006). This observation was in line with 
the results of experiments in which P2X7R was heterologously-expressed 
in lymphoblastoid or in HEK293 cells.  
These experiments showed to our surprise that basal expression of this 
receptor, far from being detrimental, produced a strong trophic activity 
(Adinolfi et al.; 2005, Adinolfi et al.; 2010).  
We investigated the biochemical basis of this trophic effect and discovered 
that was at least in part due to an enhanced mitochondrial energy state, 
to a better handling of ER Ca2+, and to a sustained activation of the 
transcription factor NFATc1 (Adinolfi et al.; 2005, Adinolfi et al.; 2009).  
Better mitochondrial performance was due to a tightly-controlled increase 
in matrix mitochondrial Ca2+ which in turn increases NADH-dehydrogenase 
activity and the overall efficiency of the respiratory chain. 
In addition to a more efficient oxidative phosphoryllation, HEK293-P2X7 
cells also have a more active glycolytic metabolism. The surprising finding 
is that lactate output was substantially increased in low glucose, both in 
HEK293-mock and HEK293-P2X7, but to a higher extent in these latter 
cells. Furthermore, in low glucose HEK293-P2X7 had a better growth 
performance. This suggests that under conditions of glucose deprivation 
cells that express P2X7 preferentially activate aerobic glycolysis and 
succeed to obtain from this metabolic pathway all the necessary energy 
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intermediates and building blocks to sustain proliferation. This switch from 
oxidative phosphorylation to glycolysis is likely due to the up-regulation in 
low glucose of two key enzymes: PK-M2 and PDHK1. PK-M2 is one of four 
PK isoforms present in mammalian cells which catalyze the 
dephosphorylation of phosphoenolpyruvate, with the net production of one 
molecule of ATP. PK-M2 has become a hot focus of investigation in 
oncology when it was discovered that not only tumours overexpress this 
isoform, but also that this enzyme is the substrate of several oncogenic 
kinases such as BCR-ABL, FGFR-1, pp60v-src (Mazurek et al.; 2011). 
As it is well known, cancer cells convert large amounts of glucose into 
lactate even in the presence of oxygen. This phenomenon bears the name 
of its discoverer, Otto Warburg, and is thus referred to as the Warburg 
effect (Cairns et al.; 2011).  
Over the years details of energy production by tumours have been 
extensively investigated and clarified, unveiling that “aerobic glycolysis” 
by no means implies that oxidative phosphorylation is shut off in cancer 
cells, but rather that these cells may have a very active aerobic 
conversion of pyruvate to lactate alongside with a normal oxidative 
phosphorylation. However, dissection of metabolic pathways involved in 
the “Warburg effect” has not been paralleled by an equally advanced 
understanding of the biological significance of this phenomenon. To this 
aim, some hint may be offered by the typical up-regulation of PK-M2 
occurring in cancer cells. In fact, this isoform in tumours is preferentially 
expressed as a dimer rather than a tetramer. Dimeric PK-M2 has lower 
affinity for enolpyruvate than the tetramer. This might appear paradoxical 
considered that cancer cells have a higher lactate output, but it is not if 
we think that by slowing down glucose degradation to lactate PK-M2 
allows the upstream building up of metabolic intermediates (e.g. glucose 
6-P, glyceraldehyde 3-P, glycerate 3-P) to be used for synthetic purposes, 
a strong requirement of actively proliferating cells (Vander Heiden et al.; 
2009). The mechanism of the preferential degradation of pyruvate to 
lactate is unknown, but it might have to do with the ability of PK-M2 to 
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associate with other glycolytic enzymes such as hexokinase, G3PDH, 
phosphoglyceromutase or enolase (Mazuerek et al.; 2011). 
The other relevant metabolic feature of P2X7-expressing cells is PDHK1 
overexpression. This enzyme catalyzes phosphorylation, and thus 
inactivation of PDH, the key enzyme for the entry of pyruvate into the 
citric acid cycle. PDHK1 is also overexpressed in cancer cells, and it is 
thought that this is another important factor that allows the preferential 
degradation of pyruvate to lactate rather than its conversion to acetyl-
CoA. HEK293-P2X7 cells also have high expression of the ubiquitous 
glucose transporter GLUT-1 and of G3PDH. Both GLUT-1 and G3PDH are 
overexpressed in highly glycolytic cells. The intriguing finding is that all 
these enzymes are up-regulated in low glucose, thus supporting a very 
active glycolytic metabolism. Alongside with overexpression of Glut-1, 
larger glycogen stores provide in HEK293-P2X7 cells fuel for glycolysis. 
It is well known that one of the mastermind factors that controls 
expression of genes involved in cellular energy metabolism is Akt/PKB 
(Feng et al.; 2010). This kinase is overexpressed in tumours, is activated 
by plasma membrane receptors for growth factors, supports aerobic 
glycolysis, modulates mitochondrial metabolism, and is also known to be 
switched on by P2X7. We found that the mere expression of P2X7 is 
sufficient to drive Akt/PKB activation, which is higher in low glucose. The 
mechanistic details of P2X7 Akt/PKB communication have yet to be 
unveiled, but it is clear that this is an additional feature that corroborates 
the strong growth-promoting effect of P2X7. 
Altogether, these data show that expression of the P2X7R induces the 
expression of several metabolic features typical of cells adapted to grow 
under limited nutrient supply, and which are also typical of cancer cells. 
These metabolic characteristics are in line with another property typical of 
cancer cells conferred by P2X7 expression, i.e. ability to grow in the 
absence of serum. Furthermore, P2X7-expressing cells also show a an 
enhanced ER Ca2+ handling, an activated NFATc1 and a more efficient 
oxidative phosphorylation. These latter feature might seem at odd with a 
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cancer phenotype, however it is now well known that mitochondrial 
function is not necessarily hampered in the mitochondria, but on the 
contrary cancer cells have often a very active and efficient oxidative 
phosphorylation. On the basis of these findings it is tempting to equate 
P2X7 to an oncogene, as this receptor confers a substantial growth 
advantage by turning on all the most important intracellular pathways 
responsible for generation of energy and for the production of the building 
blocks needed for aminoacid, lipid and nucleic acid synthesis. Thus, it 
might not be a chance finding P2X7 is overexpressed by many cancers. In 
conclusion, we have highlighted a novel metabolic activity of the P2X7R 
that sheds new light on the functions of this atypical ATP receptor and on 
the regulation of cellular energy metabolism. 
 
 
61 
 
References 
 
1.Adinolfi E, Callegari MG, Cirillo M, Pinton P, Giorgi C, Cavagna D, et 
al. Expression of the P2X7 receptor increases the Ca2+ content of 
the endoplasmic reticulum, activates NFATc1 and protects from 
apoptosis. J Biol Chem 2009; 284:10120-8. 
2.Adinolfi E, Callegari MG, Ferrari D, Bolognesi C, Minelli M et al. Basal 
activation of theP2X7 ATP Receptor Elevates Mitochondrial calcium 
and Potential, Increases Cellular ATP Levels, and promotes Serum-
indipendent Growth. Mol. Biol. Cell 2005; 16: 3260-72. 
3.Adinolfi E, Cirillo M, Woltersdorf R, Falzoni S, Chiozzi P, Pellegatti P, 
et al. Trophic activity of a naturally occurring truncated isoform of 
the P2X7 receptor. FASEB J 2010; 24:3393-404. 
4.Adinolfi E, Kim M, Young MT, Di Virgilio F and Surprenant A. Tyrosine 
phosphorilation of HSP90within the P2X7 receptor complex 
negatively regulates P2X7 receptors. J Biol Chem  2003; 278: 
37344. 
5.Adinolfi E, Melchiorri L, Falzoni S, Chiozzi P, Morelli A et al. P2X7 
receptor expression in evolutive and indolent forms of chronic B 
lymphocytic leukemia. Blood 2002; 99: 706.  
6.Airley R, Loncaster J, Davidson S, Bromley M, Roberts S et al. 
Glucose transporter glut-1 expression correlates with tumor hypoxia 
and predicts metastasis-free survival in advanced carcinoma of the 
cervix. Clin. Cancer Res. 2001; 7(4):928-34. 
7.Alcaraz L, Baxter A, Bent J, Bowers K, Braddock M. Novel P2X7 
receptor antagonists. Bioorg Med Chem Lett.   2003; 13: 4043. 
 
8.Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously 
overexpressed in 24 cancer classes. Genomics 2004; 84:1014-20. 
9.Annibaldi A, Widmann C. Glucose metabolism in cancer cells. Curr 
Opin Clin Nutr Metab Care 2010; 13:466-70. 
10.Apasov S, Koshiba M, Redegelt F, Sitkovsky M. Role of Extracellular 
ATP and P1 and P2 classes of Purinergic receptors in T-cells 
62 
 
development and cytotoxic T lymphocyte functions. Immunol Rev  
1995; 146: 5. 
11.Ardyanto TD, Osaki M, Tokuyasu N, Nagahama Y and Ito H. CoCl2-
induced HIF-1alpha expression correlates with proliferation and 
apoptosis in MKN-1 cells: a possible role for the PI3K/Akt pathway. 
Int J Oncol. 2006; 29(3):549-55. 
12.Baraldi PG, del Carmen Nunez M, Morelli A, Falzoni S, Di Virgilio F 
and Romagnoli R. Synthesis and biological activity of N-
arylpiperazine-modified anologues of KN-62, a potent antagonist of 
the purinergic P2X7 receptor. J Med Chem  2003; 46: 1318. 
13.Baricordi OR, Ferrari D, Melchiorri L, Chiozzi P et al. An ATP-
activated Channel is involved in mitogenic stimulation of human T 
lymphocytes. Blood 1996; 87:682-690. 
14.Baricordi OR, Melchiorri L, Adinolfi E, Falzoni S, Chiozzi P, Buell G 
and Di Virgilio F. Increased proliferation rate of lymphoid cells 
transfected with the P2X(7) ATP receptor. J. Biol. Chem. 1999; 274: 
33206. 
15.Beigi RD, Kertesy SB, Aquilina G and Dubyak GR. Oxidized ATP 
(oATP) attenuates proinflammatory signaling via P2 receptor-
indipendent mechanisms. Brit J Pharmacol  2003; 140: 507. 
16.Bellacosa A, Kumar CC, Di Cristofano A and Teresa JR. Activation of 
Akt kinase in cancer: implication for therapeutic targeting. Adv. 
Cancer Res 2005; 94: 29 – 86.   
17.Bianco F, Ceruti S, Colombo A, Fumagalli M, Ferrari D et al. A role 
for P2X7 in microglial proliferation. J Neurochem 2006; 99: 745-58. 
18.Blanchard DK, Mc Millen S and Djen JY. INF-gamma enhances 
sensitivity of human macrophages to extracellular ATP-mediated 
lysis. J Immunol 1991; 148 (8): 2579-2585. 
19.Borgatti P, Martelli AM, Tabellini G, Bellacosa A, Capitani S and Neri 
LM. Threonine 308 phosphorylated form of Akt translocates to the 
nucleus of PC12 cells under nerve growth factor stimulation and 
associates with the nuclear matrix protein nucleolin. J Cell Physiol. 
2003; 196(1):79-88. 
63 
 
20. Brown PD, Badal S, Morrison S, Ragoobirsingh D. Acute 
impairment of insulin signalling by dexamethasone in primary 
cultured rat skeletal myocytes. Moll.  Cell  Biochem. 2007; 297(1-
2):171-7.  
21.Bucci D, Rodriguez-Gil JE, Vallorani C, Spinaci M, Galeati G, 
Tamanini C. GLUTs and mammalian sperm metabolism. J Androl. 
2011; 32(4):348-55. 
22.Burant CF, Takeda J, Brot-Laroche E, Bell GI and Davidson NO. 
Fructose transporter in human spermatozoa and small intestine is 
GLUT5. J. Biol. Chem. 1992; 267(21):14523 – 14526.  
23.Cabrini G, Falzoni S, Forchap SL, Pellegatti P, Balboni A, Agostini P, 
et al. A His-155 to Tyr Polymorphism Confers Gain-of-Function to 
the Human P2X7 Receptor of Human Leukemic Lymphocytes. J 
Immunol 2005; 175:82-9. 
24.Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. 
Nat Rev Cancer 2011; 11:85-95. 
25.Caraynnopoulos MO, Schlein A, Wyman A, Chi M, Keembiyehetty C 
and Moley KH. GLUT9 is differentially expressed and targeted in the 
preimplantation embro. Endocrinology 2004; 145 (3): 1435 – 
1443.   
26.Chen V, Shtivelman E. CC3/TIP30 regulates metabolic adaptation of 
tumor cells to glucose limitation. Cell Cycle 2010;9:4941-53. 
27.Chiozzi P, Sanz JM, Ferrari D, Di Virgilio F. Spontaneous cell fusion 
in macrophage cultures expressing high levels of the P2Z/P2X7 
receptor. J. Cell Biol. 1997; 138:697-706.  
28.Chong JH, Zheng GG, Zhu XF, Guo Y, Wang L, Ma CH, et al. 
Abnormal expression of P2X family receptors in Chinese pediatric 
acute leukemias. Biochem Biophys Res Commun 2010; 391:498-
504. 
29.Chused TM, Aspasov S and Sitkovsky M. Murine T lymphocytes 
modulate activity of an ATP-activated P2Z type purinoceptor during 
differentiation. J Immunol. 1996; 157: 1371-1380. 
30.Cockcroft S and Gomperts BD. ATP induces nucleotide permeability 
in rat mast cells. Nature  1979; 279: 541. 
64 
 
31.Concha II, Velasquez FV, Martinez JM, Angulo C, Droppelmann A et 
al. Human erytrocytes express GLUT5 and transport fructose. Blood 
1997; 89(11): 4190 – 4195.  
32.Damdimopoulos AE, Miranda-Vizuete A, Pelto-Huikko M, 
Guastaffson JA, Spyrou G. Human mitochondrial thioredoxin. 
Involvment in mitochondrial membrane potential and cell death. J. 
Biol. Chem. 2002; 277:33249 – 33257. 
33.Delcommenne M, Tan C, Gray V, Rue L, Woodgett J and Dedhar S. 
Phosphoinositide-3-OH kinase-dependent regulation of glycogen 
synthase kinase 3 and protein kinase B/AKT by the integrin-linked 
kinase. Proc Natl Acad Sci U S A. 1998; 95(19):11211-6. 
34.Di Virgilio F, Baricordi OR, Romagnoli R and Baraldi PG. Lukocyte P2 
receptors: a novel target for anti-inflammatory and anti-tumour 
therapy. Curr Drug Targets  2204; 5: 85. 
35.Di Virgilio F, Bronte V, Collavo D and Zanovello P. Responses of 
mouse lymphocytes to ATP ex. Lymphocytes with citotoxic activity 
are resistent to the permeabilazing effect of ATP. J Immunol 1989; 
143: 1995-2001. 
36.Di Virgilio F, Chiozzi P, Falzoni S, Ferrari D et al. Cytolytic P2X 
purinoceptors . Cell Death Diff  1998; 5: 191 - 9. 
37.Di Virgilio F, Meyer BC, Greenberg S, Silverstein SC. Fc receptor-
receptor mediated phagocytosis occurs in machrophages at 
exceedingly low cytosolic Ca2+ levels. J Cell Biol  1989; 106: 657. 
38.Di virgilio F, Pizzo P, Zanovello P, Bronte V and Collavo D. 
Extracellular ATP as a possible mediator of cell-mediated 
cytotoxicity. Immunol Today 1990; 149: 3372-3378.  
39.Di Virgilio F., Chiozzi P, Ferrari D, Falzoni S, Sanz JM, Morelli A, et 
al. Nucleotide receptors: an emerging family of regulatory molecules 
in blood cells. Blood 2001; 97:587-600. 
40.Di Virgilio F., Ferrari D, Adinolfi E. P2X(7): a growth-promoting 
receptor-implications for cancer. Purinergic Signal 2009; 5:251-6. 
41.Divecha N, Rhee SG, Letcher AJ and Irvine RF. Phosphoinositide 
signalling enzymes in rat liver nuclei: phosphoinositidase C isoform 
65 
 
beta 1 is specifically, but not predominantly, located in the nucleus. 
Biochem J. 1993; 289 ( Pt 3):617-20.  
42.Doege H, Bocianski A, Sheepers A, Axer H, Eckel J et al. 
Characterization of glucose transporter (GLUT)11 (encoded by 
SLC2A11), a novel sugar –transporter facilitator specifically 
expressed in heart and skeletal muscle. Biochem. J. 2001; 359(Pt 
2):443 – 449. 
43.Donelly-Roberts DL and Jarvis MF. Discovery of P2X7 receptor 
function and indicates a role in chronic pain states. Brit J Pharmacol  
2007; 151: 571. 
44.Donelly-Roberts DL, Namovic MT, Han P and Jarvis MF. Mammalian 
P2X7 receptor pharmacology: comparison of recombinant mouse, 
rat and human P2X7 receptors. Brit J Pharmacol  2009; 157: 1203. 
45.El-Moatassim C and Dubiac G. A novel pathway for the activation of 
phospholipase D by P2Z purinergic receptors in BAC1.2F5 
macrophages. J Biol Chem  1992; 267: 664. 
46.El-Moatassim C, Bernard N, Mani JC and Donald J. Extracellular ATP 
induces a non-specific permeability of tymocyte plasma membranes. 
Biochem. Cell. Biol. 1989; 67: 495-502. 
47.Evans RJ, Lewis C, Buell G, Valera S, North RA and Surprenant A. 
pharmacological characterization of heterologously expressed ATP-
gated cation channels (P2X purinoreceptors). Mol Pharmacol  1995; 
48: 178. 
48.Falzoni S, Munerati M, Ferrari D, Spisani S et al. The purinergic P2Z 
receptor of human macrophage cells. Characterization and possible 
physiological role. J Clin Invest  1995; 95: 1207. 
49.Feng Z, Levine AJ. The regulation of energy metabolism and the 
IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 2010; 
20:427-34. 
50.Ferrari D, Los M, Bauer MKA, Vandenabeele P, Wesselborg S and 
Schulze-Osthoff K. P2Z purinoceptor ligation induces activation of 
caspases with distinct roles in apoptotic and necrotic alteration of 
cell death. FEBS Lett. 1999; 447:71-75.  
66 
 
51.Ferrari D, Pizzirani C, Adinolfi E, Forchap S et al. The antibiotic 
polymyxin B modulates P2X7 receptor function. J Immunol  2004; 
173: 4652. 
52.Ferrari D, Villalba M, Chiozzi P, Falzoni S et al. Mouse microglial 
cells express a plasma membrane pore geted by extracellular ATP. J 
Immunol  1996; 156: 1531. 
53.Filippini A, Taffs RE, Sutkovsky MV. ATP ex in T-lymphocyte 
activation: possible role in effectory functions. Proc Nat Acad Sci 
USA 1990; 87:8267-8271. 
54.Fruman DA, Meyers RE and Cantley LC. Phosphoinositide kinases. 
Annu Rev Biochem. 1998; 67:481-507. 
55.Fulda S. The PI3K/Akt/mTOR pathway as therapeutic target in 
neuroblastoma. Curr Cancer Drug Targets. 2009; 9(6):729-37. 
56.Garget CE and Wiley JS. The isoquinoline derivate KN-62 a potent 
antagonist of the P2Z-receptor of human lymphocytes. Brit J 
Pharmacol  1997; 120: 1483. 
57.Germinario RJ, Ozaki S, Kalant N. Regulation of insulin binding and 
stimulation of sugar transport in cultured human fibroblasts by 
sugar levels in the culture medium. Arch. Biochem.  Biophys. 1984; 
234(2):559-66. 
58.Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. 
Activation of the NLRP3 inflammasome in dendritic cells induces IL-
1beta-dependent adaptive immunity against tumors. Nat Med 2009; 
15:1170-8. 
59.Giorgi C, Romagnoli A, Pinton P and Rizzuto R. Ca2+ signaling, 
mitochondria and cell death. Curr. Mol. Med. 2008; 8(2): 119-30. 
60.Godlewski J, Nowicki MO, Bronisz A, Nuovo G, Palatini J, De LM, et 
al. MicroRNA-451 regulates LKB1/AMPK signaling and allows 
adaptation to metabolic stress in glioma cells. Mol Cell 2010; 
37:620-32. 
61.Gomez-Villafuertes R, del PA, Diaz-Hernandez M, Bustillo D, Diaz-
Hernandez JI, Huerta PG, et al. Ca2+/calmodulin-dependent kinase 
II signalling cascade mediates P2X7 receptor-dependent inhibition of 
neuritogenesis in neuroblastoma cells. FEBS J 2009; 276:5307-25. 
67 
 
62.Greig AV, Linge C, Healy V, Lim P, Clayton E et al. Expression of 
purinergic receptor in non-melanoma skin cancers and their 
functional roles in A431 cells. J. Invest Dermatol. 2003;  121: 315 
– 327.  
63.Gu JB, Zhang W, Worthington RA, Sluyter R, Dao-Ung P et al. A 
Glu-496 to Ala polymorphism leads to loss of function of the human 
P2X7 receptor. J Biol Chem 2001; 267: 11135- 11142. 
64.Gudipaty L, Humphreys BD, Buell G, Dubyak R. Regulation of P2X7 
nucleotide receptor function in human monocytes by extracellular 
ions and receptor density. Am. J. Physiol. Cell Physiol 2001; 280: 
C943- C953. 
65.Haga N, Saito S, Tsukumo Y, Sakurai J, Furuno A, Tsuruo T, et al. 
Mitochondria regulate the unfolded protein response leading to 
cancer cell survival under glucose deprivation conditions. Cancer Sci 
2010; 101:1125-32. 
66.Hanahan D, Weinberg RA. Hallmarks of cancer: the next 
generation. Cell 2011; 144:646-74. 
67.Heeredt BG, Huston  MA and Augenlicht LH. Growth properties of 
colonic tumor cells are function of the intrinsic mitochondrial 
membrane potential. Cancer Res. 2006; 66: 1591 – 1596. 
68.Heeredt BG, Huston  MA, Wilson AJ and Augenlicht LH. The intrinsic 
mitochondrial membrane potential (Deltapsim) is associated with 
steady-state mitochondrial activity and the extent to which colonic 
epithelial cells undergo butyrate-mediated growth arrest and 
apoptosis. Cancer  Res. 2003; 63: 6311 – 6319. 
69.Hickman SE, El Khoury J, Greenberg S, Schieren I and Silverstein 
SC. P2Z adenosine triphosphate recptor activity in coltured human 
monocytes-derived macrophages. Blood  1994; 84: 2452. 
70.Hickman SE, El-Khoury J, Greenberg S, Schieren I and Silverstein 
SC. P2Z adenosine triphosphate receptor activity in cultured human 
monocyte-derived macrophages. Blood 1994; 84: 2452-2456. 
71.Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G et al. A-
740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-
2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel 
and selective P2X7 receptor antagonist, dose-dependently reduces 
68 
 
neuropathic pain in the rat. J Pharmacol Exp Ther 2006; 319: 
1376.  
72.Humpreys BD and Dubyak GR. Induction of the P2z/P2X7 nucleotide 
receptor and associated phospholipase D activity by 
lipopolysaccaride and INF-γ in the human THP-1 monocytic cell line. 
J Immunol 1996; 157:5627-5637. 
73.Humpreys BD, Rice J, Kertesy SB, Dubyak RD. Stress 
activatedprotein kinase/JNK activation and apoptotic induction by 
the macrophage P2X7 nucleotide receptor. J Biol. Chem. 2000; 275 
(35): 26792-26798. 
74.Jacques-Silva MC, Rodnight R, Lenz G, Liao Z, Kong Q et al. P2X7 
receptors stimulate AKT phosphorylation in astrocytes. Br J 
Pharmacol. 2004; 141(7):1106-17.  
75.Jelassi B, Chantome A, Alcaraz-Perez F, Baroja-Mazo A, Cayuela ML 
et al. P2X(7) receptoractivation enhances SK3 channels- and 
cathepsin-dependent cancer cells invasiveness. Oncogene 2011; 30: 
2108-22. 
76.Kang JG, Park SY, Ji S, Jang I, Park S, Kim HS, et al. O-GlcNAc 
protein modification in cancer cells increases in response to glucose 
deprivation through glycogen degradation. J Biol Chem 2009; 
284:34777-84. 
77.Kasahara M and Hinkle PC. Reconstitution and purification of the D-
glucose transporter from human erythrocytes. J Biol Chem. 1977; 
252(20):7384-90. 
78.Kennedy HJ, Pouli AE, Ainscow EK, Jouaville LS, Rizzuto R and 
Rutter GA. Glucose generates sub-plasma membrane ATP 
microdomains in single islet beta-cells. Potential role for strategically 
located mitochondria. J Biol Chem. 1999; 274(19): 13281-91. 
79.Khakh BS, Burnstock G, Kennedy C, King BF et al. Current status of 
the nomenclature and properties of P2Xreceptors and their subunits. 
Pharmacol Rev  2001; 53: 107. International union of 
pharmacology XXIV. 
80.Kim JW and Dang CV. Cancer’s molecular sweet tooth and the 
Warburg effect. Cancer Res 2006; 66: 8927- 8930. 
69 
 
81.Kim ST and Moley KH. The expression of GLUT8, GLUT9, GLUT9b in 
the mouse testis and sperm. Reprod. Rci. 2007; 14: 445 - 455. 
82.Koivisto UM, Martinez-Valdez H, Bilan PJ, Burdett E, Ramlal T, Klip 
A. Differential regulation of the GLUT-1 and GLUT-4 glucose 
transport systems by glucose and insulin in L6 muscle cells in 
culture.  J Biol Chem. 1991; 266(4):2615-21. 
83.Krześlak A. Akt kinase: a key regulator of metabolism and 
progression of tumors. Postepy Hig Med Dosw (Online)  2010; 
64:490-503. 
84.Laine J, Künstle G, Obata T, Sha M and Noguchi M. The 
protooncogene TCL1 is an Akt kinase coactivator. Mol Cell. 2000; 
6(2):395-407. 
85.Lammas DA, Strober C, Harvey CJ, Kendrick N, Panchalingam S 
and Kumarartne DS. ATP-induced killing of mycobacteria by human 
macrophages is mediated by purinergic P2Z/P2X7 receptors. 
Immunity 1997; 7: 433-444. 
86.Lemaire I, Falzoni S, Zhang B, Pellegatti P and di Virgilio F. The 
P2X7 receptor and Pannexin-1 are both required for the promotion 
of multinucleated macrophages by the inflammatory cytokine GM-
CSF. J Immunol 2011; 187(7):3878-87. 
87.Li D, Randhawa VK, Patel N, Hayashi M, Klip A. Hyperosmolarity 
reduces GLUT4 endocytosis and increases its exocytosis from a 
VAMP2-independent pool in l6 muscle cells. J Biol Chem. 2001; 
276(25):22883-91. 
88.Li Q, Manolescu A, Ritzel M, Yao S, Slugoski M et al. Cloning and 
functional characterization of the human GLUT7 isoform SLC2A7 
from the small intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 
2004; 287(1): 236 – 242. 
89.Mackenzie AB, Young MT, Adinolfi E, Surprenant A. 
Pseudoapoptosis induced by brief activation of ATP-gated P2X7 
receptors. J Biol Chem. 2005; 280(40):33968-76. 
90.Maier A, Asano T, Volker A, Boles E and Fuhrmann GF. 
Characterization of glucose transport in Saccharomyces Cerevisiae 
with plasma membrane vesicles (co- transport) and intact cells 
70 
 
(initial uptake) with single Hxt1, Hxt2, Hxt3, Hxt4, Hxt6, Hxt7 or 
Gal2 transporters. FEMS Yeast Research 2002;  2(4): 539–550. 
91.Martelli AM, Capitani S and Neri LM. The generation of lipid 
signaling molecules in the nucleus. Prog Lipid Res. 1999; 
38(4):273-308. 
92.Martelli AM, Evangelisti C, Chiarini F and McCubrey JA. The 
phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a 
therapeutic target in acute myelogenous leukemia patients. 
Oncotarget. 2010; 1(2):89-103. 
93.Martin TE. Phopsphoinositide lipids and signaling molecules: 
common themes for signal transduction, cytoskeletal regulation, and 
membrane trafficking. Annu. Rev. Cell. Dev. Biol. 1998; 14: 231 – 
264. 
94.Mazurek S. Pyruvate kinase type M2: A key regulator of the 
metabolic budget system in tumor cells. Int J Biochem Cell Biol 
2011; 43:969-80. 
95.McCormack JG, Denton RM. The activation of isocitrate 
dehydrogenase (NAD+) by Ca2+ within intact uncoupled rat brown 
adipose tissue mitochondria incubated in the presence and absence 
of albumin. Biochem Soc Trans. 1980; 8(3): 339. 
96.McGaraughty S, Chu KL, Namovic MT, Donnelly-Roberts DL, et al. 
P2X7 –related modulation of pharmacological nociception in rats. 
Neuroscience  2007; 146: 1817. 
97.Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y et al. 
Autophagy-dependent anticancer immune responses induced by 
chemotherapeutic agents in mice. Science. 2011; 
334(6062):1573-7. 
98.Michel AD, Chambers LJ, Clay WC, Condreay JP, Walter DS, 
Chessell IP. Direct labeling of the human P2X7  receptor and 
identification of positive and negative cooperativily of binding. Brit J 
Pharmacol  2007; 151: 103. 
99.Michel AD, Clay WC, Ng SW, Roman S, Thompson K et al. 
Identification of regions of the P2X7 receptor that contribute to 
human and rat species differences in antagonist effect. Brit J 
Pharmacol  2008; 155: 738 (b). 
71 
 
100.Michel AD, Chambers LJ, Walter DS. Negative and positive 
allosteric modulators of the P2X7 receptor. Brit J Pharmacol  2008; 
153: 737 (a). 
101.Michell RH. Nuclear PIPs. Curr Biol. 1992; 2(4):200-2. 
102.Molloy A, Loachumroonvorapong P and Kaplan G. Apoptosis, but 
not necrosis, of infected monocytes is coupled with killing of 
iontracellular bacillus Calmette-Guerin. J Exp Med. 1994; 180: 
1499-1509. 
103.Morelli A, Chiozzi P, Chiesa A, Ferrari D, Sanz JM et al. 
Extracellular ATP causes ROCK I-dependent bleb formation in P2X7-
transfected HEK293 cells. Mol Biol Cell 2003; 14: 2655. 
104.Mori K. Tripartite management of unfolded proteins in the 
endoplasmic reticulum. Cell 2000; 101:451-4. 
105.Mueckler M. Facilitative glucose transporters.  Eur. J. Biochem. 
1994; 219(3):713-25. 
106.Murgia M, Hanau S, Pizzo P, Rippa M and Di Virgilio F. Oxidized 
ATP. An irreversible onhibitor of the nacrophages P2Z receptor. J 
Biol Chem  1993; 268: 8199. 
107.Mutini C, Falzoni S, Ferrari D, Chiozzi P et al. Mouse dendritic cells 
express the P2X7 purinergic receptor: characterization and possible 
partecipation in antigen presentation.  J Immunol  1999; 163: 
1958. 
108.Nakashima RA, Paggi MG, Pedersen PL. Contributions of glycolysis 
and oxidative phosphorylation to adenosine 5'-triphosphate 
production in AS-30D hepatoma cells. Cancer Res. 1984; 44(12 Pt 
1):5702-6. 
109.Neri LM, Borgatti P, Capitani S and Martelli AM. The nuclear 
phosphoinositide 3-kinase/AKT pathway: a new second messenger 
system. Biochim.  Biophys.  Acta. 2002; 1584(2-3):73-80. 
110.North RA, Barnard EA. Nucleotide receptors. Curr Opin Neurobiol  
1997; 7: 346. 
111.Paris S, Pouyssegur J and Aillhaud D. Sugar transport in chick 
embryo cardiac cells in culture: analysis by countertransport, 
72 
 
relationship to phosphorylation and effect of glucose starvation. 
Biochim. Biophys.  Acta. 1980; 602(3):644-52. 
112.Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V and Di 
Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo 
imaging with plasma membrane luciferase. PLoS ONE 2008; 
3:e2599. 
113.Pfeiffer ZA, Aga M, Prabhu U, Watters JJ, Hall DJ and Bertics PJ. 
The nucleotide receptor P2X7 mediates actin reorganization and 
membrane blebbing in RAW 264.7 macrophages via p38 MAP kinase 
and Rho. J. Leukoc. Biol. 2004; 75(6):1173-82. 
114.Phay JE, Hussain HB and  Moley JF. Strategy for identification of 
novel glucose transporter family members by using Internet-based 
genomic databases. Surgery  2000; 128(6):946 – 951. 
115.Plas DR, Talapatra S, Edinger AL, Rathmell JC, Thompson CB. Akt 
and Bcl-xL promote growth factor-independent survival through 
distinct effects on mitochondrial physiology. J Biol Chem 2001; 
276:12041-8. 
116.Raffaghello L, Chiozzi P, Falzoni S, Di Virgilio F, Pistoia V. The 
P2X7 Receptor Sustains the Growth of Human Neuroblastoma Cells 
through a Substance P-Dependent Mechanism. Cancer Res 2006; 
66:907-14. 
117.Ralevic V, Burnstock G. Receptors for purines and pyrimidines. 
Pharmacol Rev  1998; 50: 413. 
118.Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, 
Thompson CB. Akt-directed glucose metabolism can prevent Bax 
conformation change and promote growth factor-independent 
survival. Mol Cell Biol 2003; 23:7315-28. 
119.Risbud MV, Fertala J, Vresilovic EJ, Albert TJ and Shapiro IM. 
Nucleus pulposus cells upregulate PI3K/Akt and MEK/ERK signaling 
pathways under hypoxic conditions and resist apoptosis induced by 
serum withdrawal. Spine  2005; 30(8):882-9. 
120.Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J et al. 
Bicarbonate increases tumor pH and inhibits spontaneous 
metastases. Cancer Res. 2009; 69(6):2260-8. 
73 
 
121.Rozario T, DeSimone DW. The extracellular matrix in development 
and morphogenesis: a dynamic view. Dev Biol 2010; 341:126-40. 
122.Samudio I, Fiegl M, Andreeff M. Mitochondrial uncoupling and the 
Warburg effect: molecular basis for the reprogramming of cancer 
cell metabolism. Cancer Res 2009; 69:2163-6. 
123.Schenk U, Frascoli M, Proietti M, Geffers R, Traggiai E, Buer J, et 
al. ATP inhibits the generation and function of regulatory T cells 
through the activation of purinergic P2X receptors. Sci Signal 2011; 
4:ra12. 
124.Schenk U, Westendorf AM, Radaelli E, Casati A, Ferro M, Fumagalli 
M, et al. Purinergic control of T cell activation by ATP released 
through pannexin-1 hemichannels. Sci Signal 2008; 1:ra6. 
125.Schulz TJ, Thierbach R, Voigt A, Drewes G, Mietzner B et al. 
Induction of oxidative metabolism by mitochondrial frataxin inhibits 
cancer growth: Otto Warburg revisited. J. Biol. Chem. 2006;  281: 
977 -981. 
126.Schwarzer R, Tondera D, Arnold W, Giese K, Klippel A and 
Kaufmann J. REDD1 integrates hypoxia-mediated survival signaling 
downstream of phosphatidylinositol 3-kinase. Oncogene  2005; 
24(7):1138-49. 
127.Shaw M, Cohen P and Alessi DR. The activation of protein kinase B 
by H2O2 or heat shock is mediated by phosphoinositide 3-kinase 
and not by mitogen-activated protein kinase-activated protein 
kinase-2. Biochem J. 1998; 336 ( Pt 1):241-6. 
128.Sheepers A, Joost HG and Schurmann A. The glucose transporter 
families SGLT and GLUT: molecular basis of normal and aberrant 
function. J. Parenter. Enteral. Natur. JPEN 2004; 28(5):364 – 371. 
129.Shepherd PR, Gibbs EM, Wesslau C, Gould GW and Kahn BB. 
Human small intestine facilitative fructose/glucose transporter 
(GLUT5) is also present in insulin-responsive tissue and brain: 
investigation of biochemical characteristics and translocation. 
Diabetes 1992; 41(10): 1360 – 1365. 
130.Slater M, Danieletto S, Gidley-Baird A, Teh LC and Barten JA. 
Early prostate cancer detected using expression of non-functional 
cytolytic P2X7 receptors. Histopathology 2004; 44: 206 – 215. 
74 
 
131.Slater M, Danieletto S, Pooley M, Cheng TL,  Gidley-Baird A and 
Barten JA. Differentiation between cancerous and normal 
hyperplastic lobules in breast lesions. Breast Cancer Res Treat  
2004; 83:1 – 10. 
132.Solini A, Chiozzi P, Moreli A, Fellin R, Di Virgilio F. Human primary 
fibroblast in vitro express a purinergic P2X7 receptor coupled to ion 
fluxes, microvesicle formatin and IL-6 release. J Cell Sci  1999; 
112: 297. 
133.Solini A, Cuccato S, Ferrari D, Santini E, Gulinelli S et al. 
Increased P2X7 receptor expression and function in thyroid papillary 
cancer: a new potential marker of the desease? Endocrinology 
2008; 149:389-396. 
134.Steinberg TH and Silverstein SC. Extracellular ATP4- promotes 
cation fluxes in the J774mouse macrophage cell line. J Biol Chem  
1987; 262: 3118. 
135.Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. The 
cytolytic P2Z receptor for extracellular ATP identified as a P2X 
receptor (P2X7). Science  1996; 272: 735. 
136.Toker A and Newton AC. Akt/protein kinase B is regulated by 
autophosphorylation at the hypothetical PDK-2 site. J Biol Chem. 
2000; 275(12):8271-4. 
137.Ullrey D, Gammon MT, Kalckar HM. Uptake patterns and transport 
enhancements in cultures of hamster cells deprived of 
carbohydrates. Arch. Biochem.  Biophys. 1975; 167(2):410-6. 
138.Van Putten JPM and Krans HMJ. Glucose as a regulator of insulin-
sensitive hexose uptake in 3T3 adipocytes. J Biol Chem. 1985; 
260(13):7996-8001. 
139.Vander Heiden MG, Cantley LC, Thompson CB. Understanding the 
Warburg effect: the metabolic requirements of cell proliferation. 
Science 2009; 324:1029-33. 
140.Virginio C, mec-Kenzie A, North RA and Surprenant A. Kinetics of 
cell lysis, dye uptake and permeability changes in cells expressing 
the rat P2X7 receptor. J. Physiol  1999; 519: 335. 
75 
 
141.Walker PS, Donovan JA, Van Ness BG, Fellows RE and Pessin JE. 
Glucose-dependent regulation of glucose transport activity, protein, 
and mRNA in primary cultures of rat brain glial cells. J Biol Chem. 
1988; 263(30):15594-601. 
142.Walker PS, Ramlal T, Donovan JA, Doering TP, Sandra A and 
Pessin JE.  Insulin and glucose-dependent regulation of the glucose 
transport system in the rat L6 skeletal muscle cell line. J. Biol. 
Chem. 1989; 264(11):6587-95. 
143.Warburg O, Wind F and Negelein E. The metabolism of tumors in 
the body. J Gen Physiol. 1927; 8(6):519-30. 
144.Warburg O. On respiratory inpairment in cancer cells. Science 
1956; 124: 269-270. 
145.Wiley JS, Chen R and Jamieson GP. The ATP4- receptor operate 
channel (P2Z) of human lymphocytes allous Ba2+ and ethidium up-
take: inhibition of fluxes by suramin. Arch Biochem Biophys  1993; 
305: 54. 
146.Yamada K, Tilloston LG and Isselbacher KJ. Regulation of Hexose 
Carriers in Chicken Embryo Fibroblasts. J. Biol. Chem. 1982; 
258(16): 9786 - 9792. 
147.Zhang K, Kaufman RJ. The unfolded protein response: a stress 
signaling pathway critical for health and disease. Neurology 2006; 
66:S102-S109. 
